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Abstract 
Abstract 
Familial Amyloidotic Polyneuropathy is a lethal hereditary autosomal dominant disorder 
characterized by the deposition of a mutant form of the serum protein transthyretin (TTR) as 
fibrillar material in several tissues and organs. The most common form, FAP Type I or 
Portuguese, is characterized by a substitution of Met for Val at position 30 in the TTR molecule. 
It exhibits genetic anticipation, with clinical symptoms developing at an earlier age in succeeding 
generations. 
Expansion of unstable trinucleotide repeats (TNRs) is the underlying mechanism in a 
growing number of inherited human disorders exhibiting anticipation, such as Fragile X 
Syndrome, Huntington's Disease, Myotonic Dystrophy, and Friedreich's Ataxia. The number of 
trinucleotide repeats appears to be correlated with the age of onset, the severity of symptoms, or 
both. Although the pathology of FAP is produced by the deposition of amyloid derived from a 
mutant TTR, rather than the expansion of unstable TNRs, we view it possible that the 
phenotypic variability manifested as anticipation, might be related to TNR expansion in a 
modifier gene(s), rattier than TTR gene. 
Using the Repeat Expansion Detection (RED) method we have scanned affected 
members of FAP type I families from the Portuguese population to determine whether 
anticipation within such families correlated with expansion of any of the ten possible 
trinucleotide repeats. Eight generational pairs were tested; in 7 (6 parent/child and 1 uncle/niece) 
the difference in age of onset was greater than 12 years. A mother/daughter pair, with identical 
ages of onset, served as control. 
Eight of the ten possible trinucleotide repeats were successfully assayed. No major 
differences were found in the lengths of any of the repeats which could be analyzed. Expansion 
of the two untested trinucleotides as not been associated with any prior instance of anticipation. 
The observed distribution of the maximal triplet repeat sizes, as determined by the RED 
method, was consistent with previously reported studies in healthy unrelated individuals from 
several populations. 
Our results are suggestive - within the sensitivity and limitations of the RED method -
that trinucleotide repeat expansions are unlikely to be responsible for genetic anticipation in FAP 
kindreds in the Portuguese population. 
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A Polineuropatia Amiloidótica Familiar (PAF) é uma doença hereditária autossómica 
dominante letal, que se caracteriza pela deposição de uma forma mutante da proteína plasmática 
transtirretina (TTR) como material fibrilar, em vários tecidos e órgãos. A forma mais comum da 
PAF - Tipo I ou Portuguesa - é caracterizada pela substituição de uma valina por uma metionina 
na posição 30 da molécula da TTR. Este tipo de PAF apresenta antícipação genética, 
desenvolvendo-se os sintomas clínicos em idades sucessivamente mais precoces nas gerações 
seguintes. 
A expansão de repetições instáveis de trinucleotídeos ("trinucleotide repeats - TNRs") é 
um mecanismo associado a um número crescente de doenças humanas hereditárias que exibem 
antícipação, tais como o Síndroma do X Frágil, a Doença de Huntington, a Distrofia Miotónica, 
e a Ataxia de Friedreich. O número de repetições de trinucleotídeos parece estar correlacionado 
com a idade de início, a severidade dos sintomas, ou ambos. Embora a patologia da PAF tenha 
origem na deposição de TTR mutante como amilóide e não na expansão de "TNRs" instáveis, 
consideramos a possibilidade de que a variação fenotípica manifesta no fenómeno de 
antícipação possa eslar relacionada com a expansão de "TNRs" em um ou mais genes 
modificadores. 
Usando um método para a detecção de expansão de repetições ("Repeat Expansion 
Detection (RED) method "), o DNA de vários membros de famílias com PAF da população 
Portuguesa foi analisado, procurando determinar-se se existe uma correlação entre a antícipação 
observada e a expansão de repetições de qualquer um dos dez possíveis trinucleotídeos. Foram 
testados oito pares: em sete (6 progenitor/descendente e 1 tio/sobrinha) a diferença na idade de 
início da doença era superior a 12 anos. Um par mãe/filha, com idades de início idênticas, foi 
usado como controlo. 
Oito das dez possíveis repetições de trinucleotídeos foram testadas com sucesso, não 
tendo sido encontradas diferenças significativas nos comprimentos de nenhuma das repetições 
analisadas. A expansão dos dois trinucleotídeos não testados não foi nunca associada a qualquer 
circunstância de antícipação. Além disso, a distribuição dos tamanhos máximos das repetições 
de trinucleotídeos determinada pelo método RED é consistente com estudos anteriores, 
realizados com indivíduos saudáveis não relacionados entre si, de várias populações. Os 
resultados deste trabalho sugerem, dentro da sensibilidade e limitações da técnica RED, que é 
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improvável que a expansão de trinucleotídeos repetidos seja responsável pela anticipação 
genética em famílias com PAF da população Portuguesa. 
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1.1. GENERAL INTRODUCTION 
Familial Amyloidotic Polyneuropathy (FAP) is a hereditary autosomal dominant 
disorder characterized by the deposition of a mutant form of the serum protein transthyretin 
(TTR) as fibrillar material in several tissues and organs leading to death in 10 to 15 years. First 
described by Andrade in 1952, FAP has its major focus in Northern Portugal with spread to 
Japan, Sweden, Spain, and other countries. 
FAP is one of most common and best studied of the genetically related amyloidoses, a 
group of disorders characterized by the deposition of extracellular amyloid fibrils. It exhibits a 
remarkable phenotypic heterogeneity expressed in the clinical symptomatology and the age of 
onset. The variability of the disease onset in Portuguese kindreds accounts for the phenomenon 
of genetic anticipation, with clinical symptoms developing at an earlier age in succeeding 
generations. The molecular basis for anticipation in FAP remains obscure. The only known 
molecular mechanism underlying anticipation is the expansion of unstable trinucleotide repeats 
in responsible genes for a number of human hereditary dominant disorders. The identification of 
such mechanism has provided a satisfactory explanation for anticipation at the level of genomic 
DNA, and has opened the possibility to the speculate about the existence of similar repeat 
instability in the responsible or accessory genes of other familial diseases with obvious 
anticipation phenomena such as FAP. 
The first section of this chapter will refer to the general aspects of the amyloidoses, with 
particular incidence on TTR-related amyloidoses and more specifically, FAP. For a better 
understanding of FAP pathology and the disease-involved mechanisms, the biochemistry and 
molecular biology of transthyretin will be described. The phenotypic heterogeneity with special 
reference to the age of onset of the disease and the phenomenon of genetic anticipation will also 
be discussed. 
The second section will introduce the characteristics of a recently emerged mechanism 
of mutation - the unstable expansion of DNA-trinucleotide repeats. Some aspects of triplet 
repeat expansion-associated disorders will be described in detail to illustrate the connection of 
human gene mutation with pathology at the cellular level. 
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1.2. AMYLOID,AND TRANSTHYRETLN-RELATEDAMYLOIDOSIS 
Amyloidoses are diseases characterized by the aggregation of overproduced or abnormal 
proteins into stable, insoluble fibrils. The component of the amyloid deposits, initially thought to 
be a single substance;, revealed an unexpected chemical diversity when its identification was 
made possible. Different precursor proteins precipitate to form amyloid fibrils giving rise to a 
variety of clinical syndromes. The basis for the classification of the amyloidoses is presently the 
chemical nature of the: deposited protein fibrils (Table I.). 
A combination of physicochemical properties define all types of amyloid fibrils, 
regardless the precursor protein involved. The fibrillar substance can be identified by Congo red 
staining and exhibits a typical linear parallel organization on electron microscopy (Conhen et ai, 
1959). It presents a (3-pleated sheet structure, as seen by X-ray diffraction, (Eanes et al, 1968) 
and is highly insoluble; under physiological conditions. 
The major fibrillar component is always associated with a minor glycoprotein designated 
by P component which comprise about 5% of all amyloid deposits. Other extracellular 
components such glicosaminoglycans, proteoglycans, apolipoproteins (E and J) and some serum 
proteins are also part of the amyloid substance. It is not clear, however, if these molecules play 
a role in the amyloidogenesis process by inducing conformational changes on the precursor 
protein prior to its deposition, as suggested by Wisniewski & Frangione (1992), or simply 
decorate the amyloid fibrils after they are formed. 
The transthyretin (TTR) amyloidoses are the most prevalent type of genetically related 
amyloidosis and are characterized by an autosomal dominant mode of inheritance. 
The major biochemical defect underlying these diseases is the extracellular deposition of 
mutant variants of the serum protein TTR predominantly in the peripheral nerves and in the 
heart, with neuropathy and cardiomyopathy as major clinical manifestations. 
Familial Amyloidotic Polyneuropathy (FAP) was the first disorder of this group to be 
described and is characterized by the deposition of amyloid fibrils mainly in the peripheral 
nervous system, starting by the nerves of the lower limbs (Andrade, C, 1952). 
Since the description of the first cases, the number of identified kindreds with 
transthyretin amyloidosis has steadily increased leading to the identification of different clinical 
patterns of organ involvement. FAP was thus divided in four clinical types (I to IV) and the 
17 
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TABLE 1. Amyloidosis 
AL 
ALys 
APrP 
ATTR 
(3-protein precursor 
Ap2M ^-microglobulin 
AA apo-SAA 
AANF Atrial natriuretic factor 
AApoAI Apolipoprotein AI variants 
ACal Calcitonin 
ACys Cystatin C variant 
AFibA ochain fribrinogen variants 
AGel Gelsolin variants 
AH Immunoglobulin Gl 
AIAPP Islet amyloid polypeptide 
ATub 
Immunoglobulin L-chain 
Lysozyme variants 
Cellular prion protein 
Prion variants 
TTR 
TTR variants 
Tubulin fragments 
Alzeimer's disease 
Down syndrome 
Hereditary cerebral hemorrhage with 
amyloidosis - Dutch type 
Sporadic cerebral angiopathy 
Dialysis-associated amyloid 
Familial Mediterranean fever 
Musckle-Wells syndrome 
Reactive amyloidosis 
Isolated atrial amyloidosis 
Familial amyloidotic polyneuropathy - Iowa 
type 
Familial nephropathy amyloidosis 
Medulary carcinoma of thyroid 
Hereditary cerebral hemorrhage with 
amyloidosis - Iceland type 
Hereditary renal amyloidosis 
Familial amyloidosis - Finish type 
Heavy chain-associated amyloidosis 
Diabetes mellitus type II 
Insulinoma 
Idiopathic amyloidosis 
Myeloma-associated amyloidosis 
Macroglobulinemia-associated amyloidosis 
Hereditary non-neuropathic amyloidosis 
Creutzfeldt-Jacob disease (sporadic) 
Kuru 
Creutzfeldt-Jacob disease (familial) 
Gertsmann-Strussler-Scheinker syndrome 
Senile systemic amyloidosis 
Familial amyloidotic polyneuropathy 
Familial amyloidotic cardiomyopathy 
Vitreous amyloidosis 
Meningocerebrovascular amyloidosis 
Familial cerebral amyloid angiopathy-British 
term Familial Amyloidotic Cardiomyopathy (FAC) was introduced to describe a Danish kindred 
with extensive cardiac TTR deposition and very little nerve involvement (Nordlie, 1988). 
Another type of cardiac TTR-related amyloidosis is Senile Systemic Amyloidosis (SSA), 
distinguished from the other disorders by the deposition of normal TTR, rather than mutant 
forms, as amyloid fibrils in the heart. This condition is diagnosed in about 25% of individuals 
over age 80 (CornweU, 1983). 
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The primary cause of TTR-amyloid formation is believed to be the presence of point 
mutations within the TTR gene originating single amino acid substitutions in the mature protein. 
An increasing number of TTR point mutations associated with TTR-amyloidoses has been 
reported, accounting to a certain extent for the proliferation of FAP and FAC clinical subtypes. 
Nonetheless, it appears that a single pathogenic process underlies the clinical and molecular 
variations presented by the various forms of TTR-related amyloidoses. 
1.2.1. TTR: BIOCHEMISTRY AND MOLECULAR BIOLOGY 
The serum protein transthyretin was first isolated from human plasma in 1956 by 
Shultze et al. (1956). It was identified as a band migrating ahead of serum albumin on 
electrophoresis of whole plasma, and was originally named prealbumin. TTR interactions with 
circulating thyroid hormones, retinol-binding protein and other physiologically important ligands 
were progressively discovered. The innumerous studies on transthyretin make it one of the best 
studied plasma proteins reflecting the physiological importance attributed this molecule. 
1.2.1.1. TTR STRUCTURE AND PHYSIOLOGICAL FUNCTIONS 
TTR is a soluble tetrameric protein synthesized predominantly by the liver. It is 
composed of four identical subunits of 127 amino acids (Kanda et al., 1974) with a molecular 
weight of 13,745 dalton. The total mass of the circulating tetramer is 54, 980 dalton (Smith et 
al., 1979). 
X-ray diffradion analysis has revealed the three dimensional structure of TTR as a 
globular protein with substantial P-pleated sheet content and a small amount of a helix (Blake et 
ah, 1971). The secondary structure of the polypeptide chains presents 8 p-strands (identified as 
A to H) aligned in antiparallel fashion, forming two p-sheets composed of strands DAGH and 
CBEF of each monomer. The p-sheets are linked by seven loops and a single a helix segment is 
located at the end of fi-strand E (Figure 1). 
The strong interactions between strands F and H of each monomer make the TTR 
dimer, which is the teisic unit of the protein structure. 
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Figure 1. Schematic representation of the TTR dimer. 
The main physiological role of transthyretin is the transport of the thyroid hormone 
thyroxine (T4) (Fergunson, et al., 1975), and retinol (vitamin A alcohol) through the formation of 
a protein complex to retinol-binding protein (RBP) (Kanai at al., 1968). 
TTR has two structurally identical binding sites for T» (Blake et ah, 1977) and is 
responsible in humans, together with thyroxine binding globulin (TBG) and albumin, for the 
distribution of the hormone throughout the body. Although in a lower concentration in plasma 
than transthyretin, TBG carries about 70% of the circulating T4 due to a higher binding affinity 
to the molecule. In turn, TTR is believed to play a particularly important role as a T4 carrier in 
the central nervous systsm (CNS) since it is synthesized in high rate by the epithelial cells of the 
choroid plexus, and is present in high concentration in the cerebrospinal fluid. (Dickson et al., 
1986). The synthesis of TTR in the choroid plexus early in development suggests a very 
important function of the protein in the CNS presumably as a thyroxine hormone carrier. Recent 
studies with TTR knockout mice have shown, however, that T4 transport: to the brain is not 
impaired by the absence of transthyretin (Palha et al., 1997). 
Transthyretin is an important component of the retinol transport complex. It has four 
potential binding sites for RBP (van Jaarsveld et al, 1973) yet only two molecules of RBP bind 
to the TTR tetramer (Monaco et al., 1995). 
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The association with RBP protects the retinol transporter from renal catabolism and 
glomerular filtration (Raz et al, 1970) and assures the delivery of retinol to the target cells. It 
has been proposed that TTR controls the levels of circulating RBP thus regulating the 
distribution of retinol to the tissues (Sivaprasadarao & Findlay, 1988). Nonetheless, as 
demonstrated by studies with TTR null mouse strains, it is not the only mechanism for retinol 
transport and delivery: both serum RBP and retinol levels were very low but the mice presented 
a normal phenotype without any signs suggestive of retinol deprivation. (Episkopou et al, 
1993). 
In addition to RBP and T4, TTR interacts with diverse compounds including retinoic 
acid (Smith et al, 1994), noradrenaline oxidation products (Boomsma et al, 1991), hemin and 
hemoglobin (Martone and Herbert, 1993), pterins (Ernstrom et al, 1995), amyloid (3-peptide 
(Schwarzman et al, 1994), among others. The meaning of most of these interactions is still very 
obscure. 
1.2.L2. STRUCTURE, EXPRESSION AND REGULATION OF TTR GENE 
The gene encoding human TTR is a single copy gene located on the long arm of 
chromosome 18 (Whitehead et al, 1984). Assigned to region 18qll.2-ql2.1 (Wallace et al, 
1985), TTR gene contains four exons with approximately 200 bases each within about 7.0 
kilobases. The first exon encodes a signal peptide of 20 amino acid residues and the first 3 
amino acids of the mature protein; exon 2 encodes residues 4-47; exon 3, residues 48-92; and 
exon 4, the last 35 residues, from 93 to 127. The introns, designated A, B and C, span 934 bp, 
2090 bp and 3308 bp, respectively. Introns B and C contain two Alu sequences with opposite 
polarity suggesting a hairpin formation in the precursor mRNA. The first and third introns 
contain two open reading frames with respective regulating sequences. The meaning of these 
sequences is not known but it has been suggested that they might encode gene expression 
regulating proteins (Tsuzuki et al, 1985). Upstream the transcription initiation site, consensus 
sequences include a TATA box at position -30, a G+C rich region of about 20 bp, a CAAT box 
at position -101, and further up, at positions -224 and -212, two sequences homologous to 
glucocorticoid responsive elements. The (CG)n dinucleotide is the only known repeated motif in 
the entire TTR gene, including regulatory regions. Downstream the coding sequence, a 
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polyadenilation site has been located at position 123 of the 3' untranslated region (Sasaki et al, 
1985) (Figure 2). 
Circulating TTR is synthesized predominantly by the adult liver. Normal plasma 
concentration is 20-40 mg/dl (Gitlin and Gitlin, 1975) but a significant depression of this level 
occurs when the liver is participating in the acute phase response to injury or in malnutrition 
(Dickson et al, 1985; Fung et al, 1988; Murakami et al, 1988). 
TTR is also s^thesized by the choroid plexus of the brain, as demonstrated by studies 
on gene expression in rat and human (Soprano et al, 1985; Herbert et al, 1986), the synthesis 
beginning very early in development at the eighth week of gestation (Jacobsson, 1989a). This 
premature synthesis, together with a high transcriptional activity, imply a particularly important 
role for TTR in the brain. The protein is also present in the pigmented epithelium of the retina 
(Dwork et al, 1990) £ind the pineal gland (Martone, et al, 1993) in mammals. 
The human, mouse and rat TTR genes demonstrate 80% sequence homology . Amino 
acid sequence homology is even higher, of about 91% (Costa et al, 1986) with nearly complete 
conservation of sequence in the regions involved in ligand binding (Blake et al, 1978; 
Wakasugui et al, 1985). Studies on regulation and expression of mouse TTR gene were 
performed in human hepatoma cells - HepG2 - (Costa et al, 1986; Costa et al, 1989) leading to 
the identification of regulatory sequences in the human gene by comparative analysis. 
The promoter region of the human gene contains elements for hepatocyte-specific 
expression, including binding sites for HNF-1, C/EBP, HNF-3 and HNF-4. Comparative 
analysis of human and mouse sequences showed that the binding sites for 1HNF-3 and HNF-4 
are well conserved in the human TTR gene, but not those for C/EBP (Sakaki et al, 1989) 
(Figure 2). Two other liver-specific nuclear protein potential binding sites were identified in the 
human gene at positions -216 —221 and -199 ~ -204. The motif (TGG/AA/CCC/T) is 
common to factors Tf-LFl, Tf-LF2 and LF-A1. 
A region homologous to a tissue-specific enhancer of the mouse gene was found at - 3,4 
kb, containing a binding site for factor HNF-4. This region seems to be important for TTR gene 
expression in the choroid plexus. Another regulating segment, located at approximately 
6 kb of the cap site, includes a sequence with homology to binding sites for nuclear factor APF1 
(Sakaki et al, 1989). 
TTR gene expression in transgenic mice has been shown to be dependent on the 
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presence of about 600 bp upstream the transcription initiation site for hepatic and yolk sac 
expression, and 6 kb for choroid plexus expression (Yan et al, 1990; Nagata et al, 1995). 
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Figure 2. Schematic representation of the structure of the human TTR gene and localization of the 
respective regulation regions. The exons (red boxes) are numbered from 1 to 4. Alu, LI and 
(CA)n: respective repetitive sequences. TATA: TATA box; CAAT: CAAT box. Hl, C/E, H3, 
H4: binding sites of hepatocyte nuclear factors HNF-1, C/EBP, HNF-3 and HNF-4, respectively. 
Tf: common motif to Tf-LF-1, Tf-LF-2, LF-A1. Enhancer: a region highly homologous to a 
tissue-specific enhancer of the mouse TTR gene. AFP: binding site for AFP-1 factor (from 
Sakaki et al, 1989). 
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1.2.1.3. MOLECULAR TTR VARIANTS 
Following the description of the first transthyretin variant in 1984 (TTR Met30) 
(Saraiva et al, 1984), an increasing number of mutant forms were steadily identified. As 
previously referred to, the vast majority is associated with neuropathic and cardiopathie 
hereditary amyloidoses, however a number of non-amyloidogenic molecular variants have also 
been recognized (Tables 2, 3, 4, and 5). Amyloidogenic TTR Met30 is the most frequent TTR 
variant and it will be discussed later in detail. Other amyloidogenic variants occur with high 
frequency like the cardiopathie variant TTR He 122 (0,02), as determined in the Afro-American 
population by Jacobson (1992). Amyloidogenic mutant alleles are found almost exclusively in 
heterozygosity but homozygotic individuals have been reported, namely for TTR Met30 
(Holmgren et al, 1988), TTR His58 (Jacobson et al, 1994b), and TTR Ilel22 (Jacobson at al, 
1991). 
Non-amyloidogenic TTR variants are either associated with euthyroid 
hyperthyroxinemia, like TTR Thrl09, and Vall09, or do not seem to have any pathological 
effects, as observed for TTR Ser6, Asn90 and Metl 19, rather frequent in healthy carriers of the 
normal population (Jacobson et al, 1995; Alves et al, 1997). TTR Ser6 is a common 
polymorphism with an allele frequency of 0,06 in Caucasians (Jacobson et al, 1995) and the 
absence of any association with amyloidosis suggests that it is a neutral polymorphism. In 
screening studies of TTR variants in the Portuguese population (Alves et al, 1997) TTR 
Meti 19 was found to be the most frequent variant in the analyzed 5,000 individuals, the 
frequency (0,007) being very similar to that observed in other populations (Ii et al, 1992). 
Initially thought to be associated with euthyroid hyperthyroxinemia, this variant was shown not 
to have any pathogenic consequences in the Portuguese carriers. In fact, in addition to the 
referred study, several other reports suggest that TTR Metl 19 carriers are not 
hyperthyroxinemic. TTR Asn90, the second most frequent variant observed in the referred 
study, occurred with a frequency of 0,0024 and does not seem to be pathogenic, as well. 
Since the mentioned variants occur with high frequency, carriers of two different mutant 
alleles have been detected (Saraiva et al, 1991; Izumoto et al, 1993; Alves et al, 1993; 
Jacobson et al, 1994b aid Booth et al, 1994). Compound heterozygosity in the Portuguese 
population has been reported in individuals carrying both Met30/Metl 19, Asn90/Metl 19 (Alves 
et al, 1993), and Metî0/Asn90 (Saraivar al, 1991). 
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TABLE 2. Neuropathic TFR variants 
V T'ti'l1 Mutant Reference* 
remdue : . . " " " ■ ' ■ 10 Arg Cys N, CTS, C,VO,NPH Uemichi et ai, 1992; Benson and Uemichi, 1996 
18 Glu Asp N Booth et ai, 1996 
24 Ser Pro N, CTS, C Uemichi et ai, 1995 
30 Met Val N, C, VO Saraiva et ai, 1983; Tawara et ai, 1983 
30 Leu Val N Nakazato et ai, 1992; Murakami et ai, 1992a 
30 Ala Val N Jones et al, 1992 
33 De Phe N,VO Nakazato et ai, 1984 
33 Leu Phe N Hardling et ai, 1991; H et ai, 1992 
33 Val Phe N Booth et al, 1996 
34 Thr Arg N,C Patrosso et ai, 1996 
35 Asn Lys N Reilly et ai, 1995 
36 Pro .'Via N,VO Jones et al, 1991 
42 Gly Glu N Ueno et ai, 1990a 
47 Arg Gly N Murakami et ai, 1992b 
47 Val Gly N, CTS, C Booth et al, 1994 
47 Ala Gly N,C Ferlinieía/., 1994 
49 Ala Thr N, C, VO Almeida et ai, 1992 
50 Arg Ser N,C Ueno et ai, 1990a; Takahashi et ai, 1992 
50 Ile Ser N Saeki era/, 1992 
52 Pro Ser N,C,NPH Booth et al, 1994 
54 Gly Glu N Booth étal, 1994 
55 Pro l^ eu N, C, VO Jacobson et al, 1992 
58 His Leu N, CTS, C Nichols et al, 1989; Benson and Uemichi, 1996 
58 Arg l^ eu N, CTS, VO Saeki étal, 1991 
60 Ala Thr N, CTS, C Wallace et al, 1986; Benson and Uemichi, 1996 
61 Lys Glu N Shiomi étal, 1993 
64 Leu Phe N,C H étal, 1991 
70 Asn Lys N, CTS, C Izumoto et al, 1992 
71 Ala Val N, CTS, C, VO Almeida et al, 1993; Benson H et al, 1993 
77 Tyr Ser N Wallace et al, 1988 
77 Phe Ser N Bordeneuve et al, 1996 
84 Ser De N, CTS, C, VO Dwulet and Benson, 1986 
89 Gin Glu CTS,N,C Almeida et al, 1992 
91 Phe Ser N Bordeneuve et al, 1996 
97 Gly Ala N,C Yasuda et al, 1994; Nakazato et al, 1994 
107 Val He N.CTS Jacobson et al, 1994a; Uemichi et al, 1994a 
112 He Ser N,C DeLucia étal, 1993 
114 His Tyr CTS Murakami et al, 1994 
114 Cys Tyr N,VO Ueno et al, 1990b 
116 Tyr Ser N Bordeneuve et al, 1996 
122 - Vai N,C Uemichi et al, 1996 
N - Neuropathy; CTS - Csirpal Tunnel syndrome; C - Cardiomyopathy; 
VO - Vitreous opacitiesi; NPH - Nephropathy 
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TABLE 3. Cardiopathie TIR. variants 
Position Normal Mutant Phenotype References 
residue residue ■::1P™:-::: 
20 Ile Val C Jenneei al, 1996; Jacobson ef a/., 1996 
45 Thr Ala C Saraiva et al, 1992 
45 Asp Ala C,N Jacobson et al, 1994b 
50 Ile Ser C Nishiefa/., 1992 
59 Lys Thr C,N Booths ai., 1995 
68 Leu Ile C,N Almeida et al, 1991a 
111 Met Leu C Nordlie étal, 1988 
122 Ile Val C,N Gorevic e/ a/., 1989 
N - Neuropathy; C - Cardiomyopathy 
TABLE 4. Other TTR variants 
Position Normal Mutant Phenotype References 1 
residue residue -■ '■■■': ■$;■:■ i 
12 Pro Leu LD, ICH Booth et al, 1996 
18 Gly Asp CNSD Vidal eia?., 1996 
30 Gly Val VO, CNSD Herbert étal, 1994 
69 His Tyr VO Zeldenrust et al, 1994 
84 Asn Ile VO, C, CTS Skinner et al, 1992 
LD - Liver disfunction; ICH - Intracerebral hemorrhage; CTS - Carpal Tunnel syndrome; 
C - Cardiomyopathy; VO - Vitreous opacities; CNSD - Central nervous system disfunction 
TABLE 5. Non-amyloi dogenic TTR variants 
Position Normal Mutant Phenotype References 
residue residue V~": '.::"! ■;' :':-; :;:^ : :C ^  '..; :;■: :; . - ' . -: :-_::- . . ::;- . -^J"? ->-:■; :■,-:;: ■;:::::-:::--:;:. :. '.:::;:-.:;.-:.:.U.-:;:;:::; ■.; ! -1 ^j ;;■: ■■ • ■ ■ . , , : , : . . 
6 Ser Gly N Fitch etal, 1991 
74 His Asp N Uemichi et al, 1994b 
90 Asn His N Saraiva etal, 1991 
102 Arg Pro N Almeida et al, 1991b 
104 Cys Arg Neur Torres etal, 1996 
109 Thr Ala EH Moses et al, 1990 
109 Val Ala EH Refetoffeía/., 1996 
119 Met Thr N / E H Harrison et al, 1991 
N - Normal; Neur -Neuropathy; EH - Euthyroid hyperthyroxinemia 
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In some cases, as in TTR Met30/Asn90 carriers, the presence of a second mutation does not 
seem to affect the pathogenicity of Met30 (Saraiva et al, 1991). In others, as in TTR 
Met30/Metl 19 carriers, the Metl 19 mutation appears to have a protective effect on the clinical 
evolution of the disease, particularly referring to the age of onset which is later than for 
heterozygous Met30 patients (Coelho et al, 1996). 
The detection of double mutations in the same allele in two individuals - Ser6-Ile33 
(Jacobson et al, 1994b) and Asn90-Gly42 (Skare et al, 1994) - has broaden even more the 
known molecular variability of TTR. Very recently, Palha et al (1996) have reported the first 
silent mutation in transthyretin gene resulting from a C for T substitution at codon 108. 
The mutation» that originate a number of TTR variants, including TTR Met30, Ilel22, 
Thrl09 and Metl 19, occur in a CpG dinucleotide, known as a sequence with high frequency of 
mutation (Cooper and Youssoufian, 1988). The analysis of the human TTR gene demonstrates 
the existence of nutny more CpG hot spots that could originate different amino acid 
substitutions. 
Polymorphisms in the non-coding region of the TTR gene have also been shown by the 
existence of 5 different haplotypes defined by 7 intronic polymorphic substitutions (Yoshioka et 
al, 1989). Analysis of these substitutions in several individuals carriers and non-carriers of TTR 
Met30 mutation have demonstrated that none of them is related with FAP. 
1.2.2. TTRMET30AND FAMILIAL AMYLOWOTICPOLYNEUROPATHY 
In 1952, Corino de Andrade described for the first time a peculiar type of neuropathy. 
The new clinical entity was characterized as a sensory-motor neuropathy starting in the lower 
extremities, having associated a variety of symptoms in several organs which were attributed to 
an autonomic neuropathy rather than to primary disease of the organs themselves (Andrade, C, 
1952). The syndrome was latter designated by Familial Amyloidotic Polyneuropathy reflecting 
the major clinical manifestation and the hereditary nature of the disease. The first symptoms 
appear typically in the third decade of life with a slow progression to death in 10 to 15 years. 
Following the discovery of transthyretin as the major component of the amyloid fibril 
deposits by Costa et al (1978), the biochemical mechanisms involved in FAP pathology begun 
to be unraveled. The deposited TTR was reported to be a variant of the normal protein with a 
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substitution of a metMonine for a valine residue at position 30 of the polypetide chain (Saraiva et 
al. 1983) and the associated mutation at the DNA level - a single base substitution - was soon 
revealed after TTR gene cloning (Mita et al, 1984; Tsuzuki et al, 1985). TTR Met 30 was 
shown to be a biochemical marker for FAP in the Portuguese population due to the complete 
agreement between genotype and phenotype analysis in diseased individuals (Saraiva et al, 
1985). 
TTR Met30 is title most frequent mutation associated with FAP and accounts for the 
most common type of the disease, called type I or Portuguese. To date more than 500 kindreds 
with FAP have been reported in Northern Portugal, the largest focus in the world, with an 
estimated prevalence rate in 1991 of 105xl0"5 (Sousa et al, 1995) and a frequency of gene 
carriers calculated as 1 in 625. The Met30 variant is also present in other foci in Sweden, Japan, 
Spain, Italy and Brazil. Some kindreds of French, English, Cypriot, Dutch and Turkish origins 
also have this mutation (Benson et al, 1986; Saraiva et al, 1986; Holt et al, 1989; Munar-
Qués et al, 1990; Salvi et al, 1990; Ferlini et al; 1988; Hazenberg et al, 1990; Skinner et al, 
1990). Recently, FAP type I has been associated with other TTR mutations (Saraiva at al, 
1993), however, in Portugal, Brazil and Sweden, no pathogenic TTR mutations other then TTR 
Met30 have been described so far. 
Work by Yoshioka et al (1989) in Japanese FAP kindreds has shown that the Met30 
mutation occurs in a CpG hot spot and was found associated with 3 different haplotypes 
(defined by a set of 7 intronic polymorphic substitutions and classified as I, II and HI), as 
previously referred to. This observation suggested that the Val-»Met mutation has probably 
recurred in the human population to generate FAP families of independent origin. Almeida et al 
(1995) have also shown two different haplotypes associated with the mutation in European 
kindreds, substantiating ithe mutation independent origin hypothesis. Nevertheless, the possibility 
of the one founder hypothesis in Portugal and Sweden cannot be exclude, since only the 
haplotype I has been found in those areas. 
28 
Introduction 
1.2.2.1. PHENOTYPIC VARIABILITY IN TTR Met30-ASSOCIATED FAP 
The clinical phenotype first described by Andrade and thought to be "constant, repetitive 
and monomorphic" was latter revealed as being very heterogeneous in respect to the patterns of 
organ involvement and age of onset of the disease. 
A) Clinical Presentations 
Variability in. clinical manifestations secondary to variation in trie sites of amyloid 
deposition have been observed in TTR Met30 associated FAP. The classical site of amyloid 
deposition, as described by Andrade is the peripheral nervous system, giving rise to sensory and 
motor neuropathy (the majority of cases in Portugal). Amyloid deposits are also frequently found 
in the autonomic nervous system, in some cases producing the first symptoms of the disease. 
Coutinho and coworkers (1980) reviewed 483 cases of FAP type I diseased individuals showing 
a substantial variation of the first symptoms. 
Deposition of amyloid fibrils can also take place in the vitreous of the eye and in the 
kidney, producing vitreous opacities and renal disease, respectively. This phenotypes can appear 
either associated wiib. neuropathy, or as single pathological manifestations. Although such 
clinical features are not frequently observed among Portuguese patients carrying the Met30 
mutation, they have been found to arise in some families, and in some but not all branches of the 
same family. 
B) Age of Onset 
The most striiking feature of phenotypic heterogeneity in Portuguese FAP is by far the 
age of onset of the disease. The onset of TTR Met30 amyloidosis ranges from an average of 
33,5 years in the Portuguese population to an average of 56,6 years in the Swedish population 
(Sousa et al, 1995). Japanese and Majorcan populations present intermediate mean ages-at-
onset of 34,2 and 49 years, respectively (Ikegawa et al., 1991; Munar-Qués et ah, 1996). 
In the Portugese population, the age of onset varies from 17 to 78 years, with an 
average of 33,5 and a standard deviation of 9,5 years. Eighty one percent of the patients exhibit 
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the first symptoms before the age of 40 and 92% before the age of 50 years. The mean age of 
onset is significantly Irigher in females (35,6 years, SD 9,0) than in males (31,9 years, SD 9,6) 
(Sousa, A., 1995). It has also been shown that carriers of the TTR Met30 mutation could remain 
disease free up to 93 years of age (Lobato et ai, 1988; Sousa et al., 1988; Coelho étal., 1994). 
Furthermore, sporadic: cases have been reported. In a recent revision of 1,233 Portuguese FAP 
cases, neither parents of 159 individuals had shown symptoms (Coelho et al, 1994). They form 
a distinct group with an age of onset higher than the average (mean 45,1 years, SD 12,0), and 
belong to families with a geographical origin slightly different from the areas of FAP major 
prevalence. Nevertheless, this group of individuals is not significantly different from the general 
group of patients in clinical presentation at onset and severity of symptoms. 
Homozygosity of the Met30 allele has been reported in several individuals of Swedish 
kindreds but neither the clinical symptoms nor the age of onset of the disease differ significantly 
from the heterozygous individuals. Curiously, homozygous sporadic cases (in which none of the 
progenitors had shown any symptoms) have been described in the Swedish population. 
Interestingly, one of the: homozygous individuals was an asymptomatic carrier aged 62 
(Holmgren et al., 1988). It is clear, therefore, that gene dosage is not the responsible mechanism 
for the differences in the age of onset of the disease. Moreover, since the absence of normal 
alleles does not cause the disease by itself, as observed in the case of the asymptomatic 
homozygous Met30 carrier, the effect of isoalleles is also excluded as an explanation for the 
disease late onset in FAP. 
Several hypothesis have been raised to explain the existing variability of the age-at-onset 
but the underlying mechanism of such phenomenon remains obscure. No evidence has ever been 
found for the existence of a different mutation in the TTR gene segregating either with late- or 
typical onset diseased individuals. If the late-onset FAP cases were derived from a TTR 
mutation different from ttiat found in the typical forms of the disease, such mutation would have 
to occur in the noncoding region of the TTR gene, in addition to the point mutation responsible 
for the Val -» Met substitution at residue 30. Studies on TTR gene expression and structure in 
late versus typical onset FAP Met30 pedigrees (Saraiva et al, 1986) have not revealed any 
differences in TTR levels or in haplotype association. No correlation between levels of TTR 
Met30 and age or duration of clinical symptoms has been found in those kindreds. 
Although the role of environmental factors cannot be excluded, the existence of modifier 
genes involved in the TTR amyloidogenesis process is still the most attractive hypothesis to 
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explain the phenotypic variability in FAP. 
1.2.3. GENETIC ANTICIPATION IN FAP 
Genetic anticipation is a phenomenon characterized by a progressive reduction in the age 
of onset and by an increase in severity of the disease in successive generations. The finding of 
genetic anticipation was for many years attributed to ascertainment biases postulated by Penrose 
in 1948. According to Penrose, anticipation was an artifact produced by the selection of 
pedigrees, rather than a phenomenon with biological meaning. The biases were attributed to 1) 
the preferential detection of progenitors with late-onset; 2) favored selection of descendants with 
early onset (presenting more severe phenotypes); and 3) preferential detection of progenitors and 
descendants with simultaneous onset. The arguments favoring the idea of a statistical illusion 
begun to be questioned with the observation of different expressions of anticipation depending 
on the parental transmission of the disease-causing allele (Ridley et al., 1988; Hõweler et al., 
1989). A few years ago the phenomenon of anticipation was dismissed as a statistical artifact 
and a molecular mechanism explaining the perplexing features of genetic inheritance displayed 
by a number of dominant disorders was identified. 
Genetic anticipation regarding the age of onset has been for long recognized in FAP 
Met30 kindreds of the Portuguese population (Coutinho et al, 1980; Bastos Lima A, Martins da 
Silva A, 1980). Initially taken as the result of statistical artifacts, genetic anticipation in 
Portuguese FAP was latter on proved to be a real phenomenon (Sousa et al, 1990a, 1991). 
Anticipation of the age-at-onset was shown not to be the result of a simple effect of regression to 
the mean (Sousa, A., 1995). Moreover the existence of the "complementary pairs" postulated by 
Penrose (1948), i.e.., generational pairs in which the progenitors exhibit early onset and the 
descendants late onset, has never been found in Portuguese FAP kindreds. Contrarily, the age of 
onset was reported to be earlier in the second generation in the majority of cases, with a mean 
anticipation of 6,6 years, in a study of 227 generational pairs of the Portuguese population 
(Sousa, A., 1995). According to the same study, the anticipation range depends on the gender of 
the diseased individual and the affected progenitor, as male descendants of affected mothers 
have an earlier onset than female descendants of affected fathers. Sousa (1995) has also reported 
a few cases of negative anticipation, i.e., descendants with an earlier onset than the progenitors, 
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in average. These cases were mostly observed in descendants of male progenitors with early 
onset (before 30 years). 
The responsible mechanism for the phenomenon of anticipation in FAP is still unknown. 
Dynamic mutation is an attractive model as the molecular underlying cause of this perplexing 
mode of inheritance since it has been associated with other disorders exhibiting genetic 
anticipation of the age-at-onset. Presently, at least a dozen human genetic diseases have been 
shown to be caused by uinucleotide repeat expansions (TREs). Although there are 10 possible 
trinucleotide repeat motifs, only 3 [(CAG)» / (CTG)„, (CGG)n, and (AAG)n] have been 
associated with disease. The search for TREs in FAP kindreds exhibiting anticipation becomes 
the first step to identify modifier genes, suggested to underlie phenotypic variability in FAP. 
2. Dynamic mutations: trinucleotide repeat expansions (TREs) 
2.1. SIMPLE TANDEM REPEATS AND DYNAMIC MUTATION 
The human genome contains many nucleotide sequences that occur repeatedly. The 
complexity of these repeated sequences vary from complete genes (such as the ribosomal RNA 
genes) to simple sequences of one or a few base pairs. Dinucleotide repeats are among the 
simplest and most common repeats, but other frequently occurring simple tandem repeats 
(STRs) involve mono-, tri-, tetra, and pentnucleotide repeating units. The extensive 
characterization of simple repeat sequences in the human genome came about as a consequence 
of their use as highly informative genetic markers. Since their copy number is polymorphic in the 
human population aid their distribution is relatively uniform throughout the genome, simple 
tandem repeats have been used for the construction of genetic linkage maps, diagnosis by 
linkage analysis and several other purposes. The general function of the STRs (if any) is still 
unknown although sequence-specific DNA-binding proteins have been identified for di- and 
trinucleotide repeats (Richards et al, 1993), and one of the repeats can act as a preferential site 
of nucleosome assembly in vitro (Wang et al., 1994). 
A general characteristic of STRs is the instability of the repeat which appears to be a 
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function of the information content, i.e. the number of perfect repeating units. The greater the 
repeat copy number without interruptions, the higher instability it reveals. Such behavior is very 
evident in trinucleotide STRs, a feature of which is their ability to undergo dynamic mutation. 
Dynamic mutation is a process that can occur over several generations and is distinguished from 
conventional mutations by a number of properties: 1) the product of a dynamic mutation has a 
different risk of undergoing further change than the original DNA sequence; 2) the probability of 
mutation of a STR is a function of the number of perfect repeating units; 3) the mutation of a 
given repeated sequence from a harmless copy-number polymorphism to a disease causing 
unstable DNA sequence is not a single event, but a process involving multiple (sometimes 
small) changes. 
The unstable expansion of DNA-triplet repeats has recently emerged as a completely 
new mechanism of mutation. A number of disorders displaying perplexing features of genetic 
inheritance have been in recent years associated with expansion and intergenerational instability 
of stretches of identical t^rinucleotides that occur as normal shorter stable elements throughout 
the human genome. Genetic anticipation, an intriguing phenomenon observed in a significant 
number of human disorders exhibiting a dominant mode of inheritance has now been attributed 
to the expansion of unstable trinucleotide repeats. The identification of a satisfactory explanation 
for anticipation at the level of genomic DNA has led to a new series of challenges. 
2.2. PATHOLOGICAL PHENOTYPES 
Two different groups of conditions associated with triplet repeat expansion can be 
considered. One group of disorders is characterized by a progressive neuronal loss. Designated 
type I (Reddy and Housman, 1997) this group includes Huntington's disease (The Huntington's 
Disease Collaborative Research Group, 1993), spinal and bulbar muscular atrophy (SBMA) (La 
Spada et al, 1991), dentatorubral-pallidolusyan atrophy (DRPLA) (Koide et al, 1994; 
Nagafuchi et al, 1994), Machado-Joseph disease (MJD) (Kawaguchi et al, 1994) and the 
spinocerebellar ataxias (SCAs) (Orr et al, 1993; Imbert et al, 1996; Pulst et al, 1996; Sanpei 
et al, 1996; and Zhuchenko et al, 1997). The pattern of neuronal loss is different for all theses 
neurodegenerative disorders but it is, in all cases, a function of age and the size of the triplet 
repeat expansion (Table 6). 
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The other group of triplet repeat disorders includes myotonic dystrophy (DM) (Brook et 
al, 1992), fragile X syndrome (Kremer et al, 1991; Verkerk et al, 1991; Gu et al, 1996) and 
Friedreich's ataxia (Campuzano et al, 1996), designated type II diseases and involving a more 
variable pathology (Table 7). 
2.2.1. TYPE I DISORDERS 
Type I diseases are caused by moderate expansions of CAG repeats within a coding 
sequence, producing an extended stretch of polyglutamine in the corresponding protein. Several 
of this disorders have been reported to display genetic anticipation, and CAG repeat length of 
disease alleles typically correlates in an inverse manner with age of onset of the symptoms. 
Surprisingly, and in contrast with type II disorders, an increase of copy number by as little of 5% 
above a normal level can result in disease (Reddy and Housman, 1997). The number of triplets 
never exceeds 150 which probably explains why anticipation in these diseases is rather limited, 
although longer expansions in general result in earlier onset and more severe disease. In both 
type I and type II disorders, the transmission of a triplet repeats in the range of 40 to 100 repeats 
to the next generation, through either the male of female germline, exhibits mutation to a new 
repeat number with a frequency approaching 100 %. This instability contrasts with the 
transmission of repeat lengths in the order of 5-20 units were variations in size is almost never 
observed. 
Parental transmission of unstable repeats in the 40-100 repeat size range has been 
observed to present a rather different instability pattern depending on the transmitting parent 
(Brunner et al, 1993; Trottier et al, 1994). Paternal transmission gives rise to a distribution of 
repeat sizes among the offspring with a much higher median value than the repeat length of the 
father, whereas in maternal transmission the maternal mean in children remains normally 
distributed. This phenomenon already referred to as "paternal anticipation" seems to be the 
result of a significant increase in sperm TNR lengths compared to the repeat lengths of the 
father, as observed in studies of individual sperm of males with HD (Leeflang et al, 1995). 
These studies suggest that either the replication of DNA in primary male germ cells favors 
repeat expansion, or there is a selection for germ cells or mature sperm with longer TREs. 
While the disorder-related genes are widely expressed, the pathologic expression of the 
diseases is late onset and limited to specific neurological tissue of the brain. They are 
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characterized by ataxia, chorea, dementia, and in some cases psychosis. 
Table 6. Type I trinucleotide repeat diseases (from Reddy and Housman, 1997) 
Disease Repeat Clinical 
manic-station 
Sites of 
neuropathology 
Repeat Nam ber 
Normal Disease 
Location of 
the repeats 
Gene 
product 
Gene 
function 
Change in 
gene function 
Huntington's 
sTslDanB 
CAG Chorea, impairment 
of cognitive function, 
emotional 
disturbances 
Primarily in corpus 
stiatum, abo in cortex 
in late stage 
6-34 36-121 ORF HuntifltrttD Unknown Gam 
Dentatorubral-
pallidoluysian 
•trophy (Smith's 
disease) 
CAG Choreanthetosis, 
ataxia, dementia, 
myoclonus and 
epilepsy 
Globus pallidas, 
dentatorubral and 
subthalamic nucleus 
7-23 49-88 ORF Atrophia Unknown Gain 
Spinobulbar 
muscular atrophy 
(Kennedy's 
disease) 
CAG Muscle weakness, 
atrophy and 
fasciculations 
Degeneration of 
anterior horn cells, 
bulbar neurons and 
dorsal root ganglia 
11-34 40-62 ORF Androgen 
receptor 
Transcrip-
tion factor 
Gain 
SpinocerebellaT 
ataxia type 1 
CAG Ataxia, dysarthria, 
dysmetria and 
decreased vibration 
sense 
Cerebellar cortex, 
dentate nucleus and 
brainstem 
6-39 41-81 ORF Ataxin-1 Unknown Gain 
Spinocerebellar 
ataxia type 2 
CAG Ataxia, dysarthria Cerebellum, pontine 
nuclei, substantia 
nigra 
15-29 35-59 ORF Ataxin-2 Unknown Gain 
Spinocerebellar 
ataxia type 3 
(Machado-Joseph 
disease) 
CAG Ataxia, dystonia and 
ophtalmoplegia 
Substantia nigra, 
globus pallidus, 
pontine nucleus, 
cerebellar cortex 
13-36 68-79 ORF Ataxin-3 Unknown Gain 
Spinocerebellar 
ataxia type 6 
CAG Ataxia, dysarthria, 
nystagmus and 
vibratory sensory loss 
Cerebellar and mild 
brainstem atrophy 
4-16 21-27 ORF Ataxin-6 Encodes 
calcium 
channel 
subunit 
(otu) 
Gaia 
The physiological function of CAG repeats translated into polyglutamine tracts is 
unknown. Amplified CAG repeats might impair this activity (loss-of-function), or modify it 
resulting in disease (gain-of-function). The finding of normal mRNA or protein levels in these 
diseases (Strong et al, 1993; Hoogeveen et al, 1993; Banfi et al, 1994) and the absence of 
SBMA and HD phenotype in patients with deletion of the androgen receptor (Quigley et al, 1992) 
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or the HD locus (The HD Collaborative Research Group, 1993), respectively, argue against the 
loss-of-fonction effect of the CAG triplet repeats. Also, the observation that diseases such as 
HD are truly dominant with a similar phenotype in homozygotes for the disease allele (Wexler et 
al, 1987), suggest a gain of fonction. 
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Figure 3. Diagrammatic representation of type I trinucleotide repeat diseaes, showing the number and 
location of the expanded repeats within a model gene. The repeats are represented by CAG, with 
increasing font size representing expanding number of repeats. The number of repeats are shown 
on the right of the trinucleotides. The number of repeats causing disease phenotype are 
underlined. The repeat expansions in each disease gene are shown at an approximate location 
within the model gene. ORF, open-reading frame; UTR, untranslated region (from Reddy and 
Housman, 1997). 
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2.2.2. TYPE H DISORDERS 
Type II disorders exhibit a much larger range of repeat expansion lengths which 
correlates very clearly with the severity of the disease. Moreover, unlike (CAG)n-related 
diseases, triplet repeat expansions are not found in coding regions of genes but in flanking 
regions of coding sequences. Since the pathological phenotypes of fragile X syndrome, myotonic 
dystrophy and Friedreich's ataxia are very different, and the disease-associated repeated motifs 
are not a common feature as observed in type I disorders, these diseases will be discussed 
separately. 
TABLE 7. Type II trinucleotide repeat diseases (from Reddy and Housman, 1997). 
Repeat 
Clinical 
Manifestation 
Repeat Number 
Ideation of 
the repeats 
Gene 
product 
Gene 
function Disease Normal Premutation Mutation 
Change in 
gene function 
Myotonic CTG Muscle weakness, 3-37 -50-180 ~200->2000 3'UTR Myotonin Encodes 
dystrophy wasting myotonia, 
cataracts, mental 
retardation 
protein kinase 
Fragile X CGG Mental retaliation 6-52 -60-200 ~200->2000 J'UTR FMR-1 Encodes RNA- Loss 
syndrome 
(FRAXA) 
FragileX GCC Mental retardation 6-23 43-200 
syndrome 
(FRAXE) 
Friedreich's GAA Progressive gait, 7-22 
ataxia limb ataxia, 
dysarthria 
binding protein 
>200 
200->900 Intron Frataxin Unknown Loss 
The question mark indicates an unknown location, gene product, gene function or change in gene function, and the dash denotes mat the premutation is not seen 
in Friedreich's ataxia 
2.2.2.1. FRAGILEX SYNDROME 
Fragile X syndrome was the first genetic disease to be associated with the dynamic 
mutation of trinucleotide STRs (Yu et al, 1991; Oberlé et al., 1991). It is the most common 
form of mental retardation and is associated with the presence of a folate-sensitive fragile site 
{FRAXA) at chromossome Xq27.3 (Nelson D.L.,1995). Affected males have the fragile site on 
their single X chromosome and present moderate to severe mental retardation, developmental 
delay and autistic behavior. Female carriers have only mild cognitive defects and are more 
difficult to identify by cytogenetics. 
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The pattern of inheritance of fragile X shows a marked form of anticipation (Sherman el 
al, 1984). The disorder is caused by an expanded CGG trinucleotide repeat located in the 5' 
untranslated region of the FMR1 gene, which encodes a widely expressed product that has been 
characterized as a RNA binding protein (Verkerk et al, 1991; Ashley et al, 1993). This repeat 
is polymorphic in normal X chromosomes, having 6 to ~ 50 copies, typically interrupted by 
AGG triplets (Kunst, et al, 1994; Eichler et al, 1994). These chromosomes are inherited 
according to Mendelian patterns of inheritance, without expansion. At a length above ~ 50 
copies, the repeat begins to display a certain degree of instability and can increase progressively 
each time with a higher probability. Up to ~ 200 repeating units, the expansion-containing allele 
is considered in the premutation range, since it is not associated with an abnormal phenotype, 
although very unstable in intergenerational transmission. The lengths of normal and premutation 
alleles may overlap but the different stability reflects internal differences in the presence or 
location of AGG interruptions, the instability being a function of the length of the longest perfect 
CGG stretch (Eichler et al, 1994). The full mutation comprises up to thousands of copies of the 
repeated triplet originating the clinical expression of fragile X syndrome. Curiously, male 
transmission of the premutation alleles invariably remains within the premutation size range, 
while female transmitted alleles have an increasing probability of greater expansion into full 
mutation. 
Pieretti et al, 1991 have demonstrated that expansion of the CGG repeat up to hundreds 
of copies causes loss of the FMR1 mRNA. The mechanism by which the transcription ceases is 
the methylation of the CpG residues within the repeat (Oberlé et al, 1991; Wang et al, 1996). 
Thus the mode of action of FRAXA mutation is to functionally inactivate the FMR1 gene. FMR1 
protein seems to interact with other RNA-binding proteins, FXR1 and FXR2, and this complex 
presumably binds to the 60S ribosomal subunit, suggesting a role of FMR1 in modulating 
translation (Siomi et al, 1996). Whatever the role is played be this protein in the cell machinery 
it must be an important one since the absence of FMR1 protein alone leads to clinical pathology 
(De Boulle et al, 1993; Lugenbeel et al, 1995). 
Two more fragile sites (FRAXE and FRAXF) have been revealed in families displaying 
fragile X cytogenetic features but without CGG expansions (Nelson D.L., 1995). Both are 
located distal to FRAXA and exhibit GCC triplet expansions behaving similarly to the CGG 
repeat at FRAXA. FRAXE expanded alleles are associated with mild mental 
retardation while FRAXF does not have any abnormal phenotype. 
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Figure 4. Diagrammatic representation of type II trinucleotide repeat diseases, showing the number and 
location of the expanded repeats within a model gene. The repeats are represented by CTG, CGG 
and GAA, with increasing font size representing expanding number of repeats. The number of 
repeats are shown on the right of the trinucleotides. The number of repeats for pre/protomutation 
and full mutation are single and double underlined, respectively. The approximate location of the 
repeats in each disease gene is also shown in the diagram. TJTR, untranslated region (from Reddy 
and Housman, 1997). 
2.2.2.2. MYOTONIC DYSTROPHY 
It was the finding of a dynamic mutation in myotonic dystrophy that offered an 
explanation (and legitimization) of the phenomenon of anticipation by providing a clear 
biological mechanism to explain the perplexing inheritance pattern observed in this disorder 
(Suthertland et al, 1991). Myotonic dystrophy is an autosomal dominant disease characterized 
by myotonia and muscle weakness. It exhibits anticipation of severity within an affected family 
increasing over three or four generations. The mutation carriers in the earlier generation may 
have no discernible phenotypic abnormalities, or merely simple cataracts, but in succeeding 
generations there can be progressively earlier onset of muscle disease, culminating in children 
with congenital myotonic dystrophy (Harper, P.S., 1989). The length of the expanded DM allele 
is correlated with severity of the disorder, unlike in Fragile X where the length of the expanded 
trinucleotide repeat simply determines the presence or absence of symptoms. 
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The affected gene in myotonic dystrophy is located in 19ql3.3 and contains an expanded 
CTG repeat within the 3' untranslated region. It is believed to encode, by sequence homology, a 
cyclic adenosine monophosphate (cAMP)-dependent serine-threonine protein kinase designated 
by myotonic dystrophy protein kinase (DMPK), but its in vivo substrate remains unknown 
(Mahadevan et al, 1992; Fu et al, 1992; Brook et al, 1992). 
The expanded CTG stretch is highly polymorphic in the normal population ranging from 
5 to 30 repeats. The trinucleotide repeat can undergo either expansions or contractions, with a 
strong bias in favor of expansion up to many hundred repeats. In females, the size of the repeat 
can increase without apparent restrain from generation to generation reaching the point of 
genetic lethality. On the other hand, in males the repeat reaches a maximum size of -1000 
copies and then appears to decrease in size upon transmission (Lavedan et al, 1993; Mulley et 
al, 1993). Although the smaller DM alleles are more unstable in male transmissions, the very 
large alleles that transmit the most severe form of the disease are almost always transmitted by a 
female. The different meiotic behavior of the repeat in the two sexes is also observed in fragile 
X syndrome, where a female meiosis in an absolute requirement for the expression of the 
disease. This behavior contrasts with the transmission pattern observed in type I disorders that 
show much greater increases in size during paternal transmission - "the paternal anticipation" 
already referred to. 
The mechanism by which increased CTG copy number results in disease is not clear. 
Reduction of DMPK mRNA levels has been reported (Fu et al, 1993), but the absence of point 
mutations in the gene giving rise to a phenotype similar to DM, together with the dominant 
nature of the disease, argue against the hypothesis of DMPK gene loss of function to be the 
cause of DM pathology. Alternatively, Boucher et al (1995) have suggested that the CTG 
repeat expansion has an effect on the neighboring genes, contributing in such manner to 
myotonic dystrophy pathology. 
2.2.2.3. FRIEDREICH'S ATAXIA 
Friedreich's ataxia is the most recent disorder found to be associated with trinucleotide 
repeat expansions (Campuzano et al, 1996). It has joined the type II disease group exhibiting 
the expansion of a new disease-related triplet: GAA. As an autosomal recessive disease with 
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little evidence for genetic anticipation, FA does not fit the mold of a dynamic mutation. Although 
the age of onset may vary, most patients exhibit the symptoms in adolescence and the onset in 
middle age or later is mostly uncommon, unlike the other triplet diseases with anticipation. 
The GAA repeat is located within the first intron of frataxin gene which encodes a 
protein of unknown function. The normal alleles include 10 to 21 copies of the repeat whereas 
nearly 95% of FA alleles contain from ~ 200 to 900 copies - similar to the premutation alleles 
found in FRAXA and DM. Recently, premutation alleles of around 40-60 GAAs have been 
reported in FA (Cossée et al, in press). The disease-causing expansion appears in 
heterozygosity in about 90% of the patients, but half of the remaining are compound 
hétérozygotes carrying the repeat expansion in one allele and point mutations in the other. 
The expanded GAA repeat in intron 1 appears to interfere in frataxin nuclear RNA 
processing resulting in the absence of a mature message in the cytoplasm (Campuzano et al, 
1996). Although such hypothesis has not been proved, the massive number of AG splice 
acceptor sites formed by the expanded GAA repeating units, is likely to underlie the mechanism 
by which the transcript levels are reduced in FA. Moreover, the GAA repeat cannot form 
hydrogen-bonded hairpins, thus being unable to form the non-conventional DNA structures 
characteristic of CG-rich repeats, which may be involved in DNA transcription impairment in 
other TREs-associated diseases. 
2.2.3. OTHER DISORDERS 
Recent studies have shown that the expansion of a 12-bp repeat is responsible for a 
monogenic form of epilepsy known has progressive myoclonus epilepsy (EPM1) (Lalioti et al. 
1997; Lafrenière et al, 1997; Virtaneva et al, 1997). The gene encoding cystatin B, a 
proteinase inhibitor, contains a (CCCCGCCCCGCG)3 in the 5' flanking region within the 
promoter sequence which expands up to 600-900 bp in diseased alleles. EPM1 is the second 
autosomal dominant disorder joining the growing number of genetic diseases that are associated 
with unstable repeat expansions. 
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Experimental Research 
Objectives 
Experimental Research 
1. Objectives 
The molecular mechanisms underlying genetic anticipation in FAP remain one of the 
major unsolved dilemmas concerning the phenotypic variability presented by this disorder. As a 
neurological disease with an autosomal dominant mode of inheritance and evident anticipation, 
FAP is a strong candidate for the involvement of trinucleotide repeat instability in the decreasing 
age of onset over successive generations. The pathology of FAP is produced by point mutations 
in the TTR gene, rather than unstable trinucleotide repeat expansions. Indeed, TTR gene 
structure does not include repeated triplets neither within the coding regions nor in the 
untranslated regulatory sequences (Sakaki et al, 1989). Since TTR amyloidogenesis is a 
multistep process, modifier gene(s) are very likely to be involved in phenotypic variability 
manifested as genetic anticipation. We have questioned whether anticipation in FAP might be 
related to unstable trinucleotide repeat expansions in a modifier gene (or genes), rather than 
TTR gene itself. 
The main purposes of this project were 1) the determination of maximal trinucleotide 
repeat lengths in generational pairs of Portuguese FAP kindreds, and 2) the detection of 
intergenerational instability of any of the ten trinucleotide repeats in the same kindreds. 
We have performed a complete genome scanning of trinucleotide repeat lengths in 8 
generational pairs of FAP Portuguese families with a difference in age of onset greater than 12 
years, using the Repeat Expansion Detection (RED) method. This technique does not require 
flanking sequence information and allows a genome-wide search for potentially pathological 
repeat expansions. 
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2. Materials and Methods 
2.1. GENERATIONAL PAIRS AND CONTROLS 
Eight generational pairs of Portuguese kindreds with FAP were scanned for trinucleotide 
repeat expansions using the RED method. In seven of the tested pairs the differences in the age 
of onset were greater than 12 years. One pair with identical ages of onset was used as a control. 
The gender and age-at-onset of the individuals of each pair are described in the following table. 
All affected individuals were confirmed carriers of the TTR Met30 mutation, and were 
diagnosed as FAP patients based on the presence of characteristic clinical features of the 
disorder. The two asymptomatic individuals did not exhibit any pathological symptoms, 
although confirmed carriers of the TTR Met30 allele. None of the above individuals had the 
TTR Metl 19 mutation. 
As negative controls, nineteen unrelated individuals of the Portuguese population 
without known genetic disease (11 females, 6 males and 2 individuals of unknown gender) were 
used. 
Blood samples were collected using vacutainer tubes with ACD (Becton Dickinson) for 
lymphocyte immortalization and DNA extraction. 
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2.1.1. LYMPHOCYTE IMMORTALIZATION 
A 3.0 ml whole blood aliquot was carefully laid onto 3.0 ml of Histopaque-1077 
(Sigma) (previously brought to room temperature), on a 15 ml centrifuge Falcon tube. This 
mixture was centrifuged at 1800 rpm, for 30 minutes, at room temperature. 
After centrifugation, the upper layer to within 0.5 cm of the opaque interface, was 
carefully aspirated using a Pasteur pipette and discarded. The opaque interface, containing 
mononuclear cells, was then transferred with a Pasteur pipette into a clean centrifuge Falcon 
tube. Ten ml of RPMI-1640 Medium (Sigma) were then added to the tube, and the contents 
were mixed by gentle aspiration. 
After a centrifugation at 1400 rpm, for 10 minutes, the supernatant was discarded and 
the cell pellet was resuspended in 5.0 ml of RPMI-1640 medium. Another centrifugation 
followed, at 1400 rpm, for 10 minutes, the supernatant was discarded and the cell pellet was 
once again resuspended in RPMI-1640 medium and then centrifuged one last time at 1400 rpm, 
for 10 minutes. 
Using a Pasteur pipette, the resulting cell pellet was resuspended in 2.0 ml of RPMI-
1640 medium and the transformation step followed. 
TRANSFORMATION BY EPSTEIN-BARR VIRUS (EBV) 
A 2.0 ml volume of Transformation Medium was added to 1.0 ml of resuspended cell 
pellet obtained by the procedure described above, and 1.5 ml aliquots of the mixture were 
transferred to a couple of 25 cm3 culture flasks. 1.5 ml of EBV suspension (previously 
incubated at 37°C for 3-4 hours) was added to each flask. 
After 24 hours, 2.0 ml of Transformation Medium were added to the culture, and this 
procedure was continued in each two days, for a week, after which the medium was transferred 
to a clean centrifuge Falcon tube followed by a centrifugation at 1200 rpm, for 10 minutes. Half 
of the supernatant volume was discarded and replaced with the same volume of Complete 
Medium. 
In each two days that followed the previous step, a given volume of Complete medium 
(depending on the evolution of the culture) was added. After a week or two, the cells 
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were transformed and could by frozen for storage. 
FREEZING OF LYMPHOCYTES 
A 1.0 ml volume of Freezing Medium (Gibco), previous placed on ice, was added to 1.0 
ml of resuspended cell pellet, very slowly and using a Pasteur pipette. During this step, the tube 
containing the cells was kept on melting ice and was continuously shaken. 
The mixture was then transferred to a Nunc Vial freezing tube and stored at -70°C for 
at least 4 hours up to 24 hours, after which the tube was conserved in liquid nitrogen. 
CULTURE OF FROZEN LYMPHOCYTES 
One ampoule containing the frozen cells, was removed from the liquid nitrogen and 
immediately thawed in a shaking water bath at 37°C. Before the disappearance of the last ice 
crystals, the tube was placed on ice and the cell suspension was very carefully transferred to a 
centrifuge Falcon tube, containing 5.0 ml of base Medium supplemented with 20% FCS, at 4°C. 
After centrifugation at 1200 rpm, for 10 minutes, the supernatant was discarded, and the 
cell pellet resuspended in 2.0 ml of Complete Medium (supplemented with 20% FCS). The 
suspension was then transferred to a 25 cm2 flask and, following an incubation at 37°C, for 24 
hours, 2.0 - 6.0 ml of Complete Medium were added. 
Depending on the evolution of the culture, each two days, a given volume of Complete 
medium was added, until the culture reached the desired point. 
MEDIA 
Base Medium 
This medium contains 500.0 ml of RPMI-1640 with L-glutamine and Hepes (Gibco), 
2.0 ml of penicillin/streptomycin (Gibco), 2.0 ml of kanamycin (25 mg/ml) and 5.0 ml of 
fungizone (250ug/ml). After preparation was stored at 4°C. 
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Complete Medium 
This medium contains 100.0 ml of Base Medium; 5.0 ml of foetal calf serum (FCS), 
previously inactivated at 56°C, for 30 minutes and 1.5 ml Ultroser HY hydrated (Gibco). After 
preparation this medium was stored at 4°C. 
Transformation Medium 
This medium contains 100.0 ml of Base Medium, 20.0 ml of FCS (previously 
inactivated at 56°C, for 30 minutes) and 0.15 ml of ciclosporin (1 mg/ml in ethanol). 
Freezing Medium 
This medium contains 0.8 ml of FCS (previously inactivated at 56°C for 30 minutes) 
and 0.2 ml of sterile DMSO. After preparation was stored at -20°C. 
2.1.2. GENOMIC DNA EXTRACTION 
Twelve ml of total blood were centrifuged at 2,000 rpm for 10 minutes. The plasma 
layer was gently removed and the buffy coat - the leukocyte layer - was carefully placed in 
eppendorf tubes. 1-2 volumes of a solution containing 72.0 mg of ammonium bicarbonate and 
7.0 g of ammonium chloride in a liter of dd H2O were added to the cells for erythrocyte lysis. 
The tubes were left on ice for 10 minutes, centrifuged at 10,000 rpm for 5 minutes, and the 
supernatant discarded. This procedure was repeated a number of times in order to obtain a clear 
white cell pellet. 
A 5.0 ml volume of proteinase K buffer (Tris 0,05M pH 7,5; NaCl 1M; EDTA 0,001M; 
and SDS 0,5%) was added to the cell pellet followed by 50.0 ul of proteinase K and incubated 
overnight at 55 °C. Following the leukocyte lysis, 2.0 ml of an NaCl saturated solution and 2.0 
ml of chloroform were added to the pellet and vortexed for 30 seconds. After a centrifugation at 
9,000 rpm for 10 minutes, the supernatant was discarded and 2 volumes of 100% ethanol were 
added to the tube which was inverted until DNA visualization. The precipitated DNA was 
remove carefully and resuspended in an appropriate volume of TE buffer. 
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2.2. RED METHOD 
Repeat Expansion Detection (RED) method is a generally applicable method which 
provides a direct path to identify potentially pathological repeat expansions (Schalling et al, 
1993). Single copies of large trinucleotide repeats can be detected based on the use genomic 
DNA as a template for the annealing and ligation of repeat-specific oligonucleotides. 
Consequently, it does not require flanking sequence information, or single copy probes. A 
thermostable ligase is used in a cycling procedure which generates multimers of the 
oligonucleotide used. 
This method constitutes a unique way of studying triplet repeat expansion-associated 
inherited disorders, particularly those characterized by anticipation. 
2.2.1. GENERAL PRINCIPLE 
The genomic DNA containing a long segment of repeated trinucleotides serves as a 
template for annealing of oligonucleotides composed of several copies of the complementary 
triplet (Figure 5). As two or more oligonucleotide molecules anneal to the genomic template in 
adjacent positions, they are ligated by a thermostable ligase, forming a longer single stranded 
molecule. This step is repeated several hundred times in a two-step cycling process using 
adequate denaturation and annealing temperatures. The presence of long trinucleotide repeats 
anywhere in the genome will give rise to the formation of large multimers of the original 
oligonucleotide. The single stranded multimers are separated by size in denaturing conditions by 
polyacrylamide gel electrophoresis, transferred to a nylon membrane and detected by 
hybridization to a 32P-labeled complementary oligonucleotide. The radiolabeled probe 
maximizes the detection of the RED reaction products. 
2.2.2. OLIGONUCLEOTIDE PHOSPHORYLATION 
For 20 RED reactions 100 ^1 of T4 polynucleotide kinase (Epicentre) mixture was 
prepare by combining 73.0 |al of ddH20; 10.0 ^1 of ATP (10 mM); 10.0 [Ú of lOx T4 
polynucleotide kinase buffer; 1.0 \x\ of the testing oligonucleotide (1 or 2 ug/ul depending on 
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the length of the oligo, being the higher concentration for oligonucleotides with about 17 
repeated units); and 6.0 ul of T4 polynucleotide kinase (PNK). The reaction mix was incubated 
at 37 °C for 50 minutes and used in the RED reaction immediately. Alternatively, the mixture 
can be heated at 65 °C to inactivate PNK and stored at -80 °C for posterior use. 
(CTG),o OLIGONUCLEOTIDES 
ANNEALING 
— i i i i i n i i i i i i i n i n 
CAG REPEAT 
IBB i m in i imn imiH I I I 'P" 1 "— 
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* t ^ ^ 
i - iTTHiHi inmim i i i n i i i i m i i i i i j i i u i i j u i i j j i m i u i i i i i i i i i i = 
1 DENATURATION 
PRODUCTS = MULTIMERS OF (CTG)io OLIGONUCLEOTIDES 
Figure 5. Diagram depicting amplification and detection of DNA-trinucleotide repeat using RED. Since 
only one strand of oligonucleotide multimer is produced per target molecule per cycle, a large 
amount of DNA is needed (10 ug). Products vary in length as multimers of the oligonucleotide 
used, and depend upon size of the target (from Schalling et ai, 1993). 
2.2.3. REACTION CONDITIONS 
Following the addition of 5.0 ul of phosphorylated oligonucleotide to -10.0 ul of DNA 
template (~ 1 ug/ul), the reaction mixture was covered with 20.0 ul of mineral oil in eppendorf 
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tubes, heated at 98 °C for 10 minutes, to denature the DNA, and placed on ice (for CGG 
oligonucleotide, 10.0 jul of 5M Betaine were added to the mixture). While keeping the samples 
on ice, 10.0 ul of ligation reaction mix A containing: 2.0 ul of lOx Ampligase reaction buffer; 
7.0 ul of ddH20; and 1.0 ul of Ampligase DNA ligase (5 Units) (Epicentre). The reaction 
mixtures were quickly centrifuged for 30 seconds, and the tubes were placed into the 
thermocycler (Perkin Elmer DNA Thermal Cycler) for cycling according to the following 
parameters: 
For (CTG)io/n-, (CGG)n- (TGG)i2-, and (CGT)i4-oligonucleotides - 100 cycles at 70 °C for 
30 seconds and 95 °C for 10 seconds; for (CCT)i5-, (AAG)io-, (GTT)i5,- (AGT)H-, and 
(ATG)i2- oligonucleotides - 100 cycles at 60 °C for 30 second and 95 °C for 10 seconds; for 
(TAA)n -100 cycles at 50 °C for 30 seconds and 95 °C for 10 seconds. 
After the first 100 cycles, the samples were placed on ice and 5.0 ul of ligation reaction 
mix B containing: 3.5 ul of ddH20; 0.5 ul of lOx Ampligase reaction buffer; and 1.0 ul of 
Ampligase DNA ligase (5 U), were added. The samples were quickly centrifuged for 30 
seconds and the cycling was restarted for 300 additional cycles at the same conditions described 
above. The RED reaction products were immediately used for electrophoretic separation or 
stored at 4 °C. 
2.3. ELECTROPHORESIS 
The mnning gel consisting of 50.0 ml of a pre-warmed 6% acrylamide / 6M urea 
solution, 500.0 ul of APS and 35.0 ul of TEMED was poured into a SequiGen II electrophoresis 
apparatus (0.5 mm thick) (Biorad) and pre-run at 50 watts for 30 minutes. Meanwhile 20.0 ul of 
the RED reaction products were mixed with 15 ul of gel loading dye, denatured for 5 minutes at 
95 °C and placed on ice. 
Following the gel pre-run (30 minutes), the wells were cleaned with a Pasteur pipette to 
prevent urea deposits, the samples were loaded, and the gel was run in lx TBE for 
approximately 1 hour and 10 minutes at 50 watts (the xylenocyanol dye should migrate to 
middle of the plates). The intact gel apparatus was then put under cold tap water for 10 minutes. 
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2.4. MEMBRANE TRANSFER 
A Hybond N+ membrane (Amersham) was quickly soaked in lx TBE and placed in 
direct contact with the gel. The membrane was then covered with 3 layers of 3M paper and the 
glass plate was placed on top. The RED products were left transferring by capillary action 
overnight. 
The membrane was removed, rinsed for 2 minutes in 2x SSC, dried at room 
temperature for 1 hour and exposed to UV light to cross-link the DNA to the membrane. 
Following this procedure, the membrane could be immediately hybridized or stored at room 
temperature. 
2.5. LABELING OF THE PROBE 
The probe was radiolabeled by combining 1.5 ul of the probe (200 ng/ul); 6.5 ul of 
ddH20; 4.0 ul of 5x terminal transferase buffer; 2.0 ul of CoCfe; 5.0 ul of P32-dCTP; and 1.0 ul 
of terminal deoxynucleotidyl transferase (Boehringer Mannheim) in an Eppendorf tube. 
Following the incubation for 60 minutes at 37 °C, 4.0 ul of glycogen solution (20 ug/ul) and 
50.0 ul of 100% ethanol were added, followed by a centrifugation for 30 seconds. The ethanol 
was carefully removed and the precipitated DNA was dried in the speedvac for at least 60 
minutes. The radiolabeled DNA was finally resuspended in 100.0 ul of ddH20. 
2.6. HYBRIDIZATION 
The dried membranes were pre-hybridized in Rapid-Hyb buffer (Amersham) for at least 
1 hour at the following temperatures: for (CTG)io/n-, (CGG)u-, (TGG)i2-, and (CGT)M-
oligonucleotides - at 65 °C; for (CCT)i5-, (AAG)io-, (GTT)i5,- (AGT)14-, and (ATG)i2-
oligonucleotides - at 60 °C; for (TAA)n - at 55 °C. The hybridization with the radiolabeled 
probe was done overnight in the same buffer at the same temperature. After 2 washes in 2x SSC 
(20 minutes each) at room temperature, followed by 2 washes in lx SSC (30 minutes each) at 5 
°C below hybridization temperature, the membrane was exposed to Kodak X-AR 
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or Kodak Biomax MS films at -80 °C, using intensifying screens, for 1-15 days. 
52 
Results and Discussion 
3. Results and Discussion 
3.1. CTG/CAG TRINUCLEOTIDE 
Eight inherited neurodegenerative disorders are known to involve expansions of CAG 
trinucleotide repeats within susceptibility genes, resulting in an abnormally long stretch of 
polyglutamine within the encoded proteins. CTG repeat expansions are associated with severe 
phenotypes of congenital myotonic dystrophy as long segments of the repeated triplet in the 3' 
untranslated region of the myotonin gene result in disease. These inherited diseases, in which the 
length of the CTG or CAG repeat region is expanded, exhibit genetic anticipation. 
We have tested the genomic DNA from 9 FAP kindred pairs and 8 negative controls 
using (CTG)io and (CTG)n oligonucleotides to assess trinucleotide repeat lengths and to detect 
the existence of possible expansions eventually responsible for genetic anticipation in FAP. 
Some generational pair and control DNAs have been tested in duplicate or triplicate to confirm 
the results obtained for this particular trinucleotide, and to define the reproducibility of RED in 
our laboratory. As a positive control, the DNA of an individual exhibiting a very long stretch of 
the repeated motif was used in all reactions. The RED reaction results are shown in the 
autoradiographs of Figures 6, 7, 8, and 9. 
All samples of seven of the eight pairs exhibited a maximal repeat size of 120 bp, 
corresponding to 40 repeated triplets. Only pair IV has broken the consistency of the repeat 
length distribution in FAP gene carriers by exhibiting a fragment of 210 bp corresponding to 70 
copies of the trinucleotide (Fig. 6, lanes 11 and 12; Fig. 8, lanes 4 and 5; Fig. 9, lanes 8 and 9). 
No differences in maximal repeat size have been found within the tested pairs with the exception 
of an extra pair used only in CTG/CAG repeat detection experiments - pair Y. The descendant, 
diseased with an onset at 40, presents a slightly longer repeat than the progenitor, asymptomatic 
carrier, corresponding to the ligation of one more (CTG)io oligonucleotide referring to a 30 bp 
(10 copies) difference (Fig. 6, lanes 1 and 2). The control samples have shown repeat lengths 
ranging between 60 bp (20 repeats) and 270 bp (90 repeats). CTG/CAG repeat sizes, as 
determined by RED, are compared in Figure I. 
CTG/CAG repeats are highly polymorphic in length in the human genome but their 
number usually does not exceed 40 repeats in normal individuals. Hofferbert et al. (1997) have 
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reported, however, repeat sizes ranging from 120 bp to 270 bp as determined by RED in 74 
unrelated control individuals, that is, a triplet copy number of 40 to 90 repeats. The existence of 
such unexpected high triplet copy number in normal individuals has been confirmed in a study 
on 75 normal Japanese individuals and 30 randomly chosen healthy Caucasians (Nakamoto et 
al., 1997). According to this report, the length of the polymorphic CAG/CTG repeats ranges 
from 10 to 92 in the Japanese and Caucasian individuals sample, the frequency being much 
higher for repeat copy number between 10 and 30 repeats, as expected. Our results fall in the 
expected range of the reported size spectrum, not exceeding 70 repeats in the FAP kindred 
individuals and 90 repeated units in the unrelated healthy controls. 
Pairs I and IV were also tested using a longer oligonucleotide - (CTG)n. The repeat 
lengths have shown good correlation with both oligonucleotide substrates, presenting identical 
sizes (Figure 6 and 7). The samples scanned in duplicate or triplicate (pairs I, JJ, IV, and 
controls N3, N4) also show identical triplet sizes in different reactions, demonstrating the 
reproducibility of the RED assay. 
Some samples exhibit CTG/CAG repeat segments with sizes corresponding to CTG 
repeat lengths of myotonic dystrophy premutation alleles, and to CAG repeat lengths of disease-
causing alleles of neurological disorders like HD, DRPLA, Kennedy's disease and SCA3. 
Nonetheless, our results clearly exclude the existence of unstable CTG/CAG repeat expansions 
from one generation to another in FAP-diseased individuals exhibiting genetic anticipation, 
making TREs an unlikely explanation. 
3.2. AAG/CTT TRINUCLEOTIDE 
The autoradiographs shown in Figures 10, 11 and 12 represent RED reaction products 
of seven generational pairs tested for the presence of AAG/CCT trinucleotide repeat expansions. 
The oligonucleotide used in the cycling reaction was an (AGG)io. 
Trinucleotide repeat lengths range from 110 repeated units (330 bp) up to 200 triplets 
(600 bp) in the tested pairs. The controls vary between 70 (210 bp) and 170 repeats (510 bp) 
(Figure II). No significant differences in repeat size are observed within 6 of the 7 pairs, the 
major difference being the ligation of two more (CTG)io-mers in the progenitor of pair I that has 
the same age of onset as the daughter, representing a putative contraction of the repeated motif. 
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Figure I. Maximal sizes of CTG/CAG repeat multimers in FAP kindred pairs and 
unrelated controls as determined by RED. 
700 
■ Progenitor ■ Descendant ■ Average 
Pair III Pair IV PairV Pair VI Pair VII Controls 
Figure II. Maximal sizes of AAG/CTT repeat multimers in FAP kindred pairs and 
unrelated controls as determined by RED. 
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Figure 6. Autoradiograph of the RED reaction products using (CTG)i0 and (CTG)17 oligonucleotides 
(lanes 1-7 and 8-14, respectively). PC: positive control; lanes 4, 5 and 9-12: FAP generational 
pairs; lanes 6 and 7: control individuals. The remainder lanes refer to samples excluded from 
our study. Note the correlation of repeat sizes obtained with both oligonucleotide substrates. 10 
ug of genomic DNA template were used in each reaction. Sizes of (CTG)„ multimers are 
indicated in bp. 
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Figure 7. Autoradiograph of the RED reaction products using (CTG)10. Lanes 1-6: FAP generational pairs. 
10 ug of genomic DNA template were used in each reaction. Sizes of (CTG)n multimers are 
indicated in bp. 
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Figure 8. Autoradiograph of the RED reaction products using (CTG)i0. Lanes 2-9: FAP generational pairs; 
lanes 10-12: control individuals; PC: positive control. 10 ug of genomic DNA template were 
used in each reaction. Sizes of (CTG)n multimers are indicated in bp. 
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Figure 9. Autoradiograph of the ÎŒD reaction products using (CTG)i0. Lanes 2-9: FAP generational pairs; 
lanes 10-13: control individuals; PC: positive control. 10 ug of genomic DNA template were 
used in each reaction. Sizes of (CTG)„ multimers are indicated in bp. 
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A difference in one ligation is also observed in pair II (Fig. 12, lanes 2 and 3). The accuracy of 
band reading at the upper portion of the gel is slightly diminished by a progressive loss of 
resolution which might explain the small differences found in pairs I and H. 
The length of the AGG repeat could not be determined for the descendant of pair IV 
(Fig. 12, lane 10) and for some controls (Fig. 11, lanes 4, 5; and Fig. 12, lanes 11, 13) due to a 
weak cycling reaction which could not produce the necessary amount of (AAG)io multimers for 
exact size detection. 
Our results show the absence of AAG/CTT repeat expansions in the second generation 
elements of the tested pairs, thus excluding the involvement of such mechanism as the molecular 
basis of genetic anticipation in these pedigrees. The maximal number of copies is consistent with 
previously reported studies in unrelated Caucasians (Hofferbert et al., 1997) where it ranges 
from 252 bp to 540 bp. 
AAG trinucleotide repeat expansions are associated with Friedreich's ataxia. Long 
stretches of the AAG repeated motif are located within an intronic sequence of the frataxin gene 
leading to the loss of function of the protein. The mutation-causing repeat number ranges 
between 200 and > 900 triplets, while the results show a triplet repeat with similar length in one 
patient - the progenitor of pair I - containing 200 copies, with a phenotype typical of FAP 
classical onset. The length of the repeat is highly polymorphic and such high copy number is not 
uncommon in normal individuals. 
3.3. TTA/TAA TRINUCLEOTIDE 
The products of the RED reaction of TTA/TAA triplet are shown in Figure 13. All 
samples show a ligation product of 66 base pairs corresponding to a dimer of the (TTA)n 
substrate. The samples refer to three FAP generational pairs (I, II and HI) and 7 control 
individuals. RED reaction has produced low and unequal amounts of oligonucleotide dimers but 
the single band is clearly visible for all samples in which the reaction has worked. No larger 
multimers have been formed which is in accordance with the study by Hofferbert et al. (1997) 
where a single ligation corresponding to 72 bp was expected as the maximal repeat length 
determined for the 52 tested unrelated individuals. The discrepancy of size in base pairs is due 
to the triplet copy number of the oligonucleotide used in both RED studies. 
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Figure 10. Autoradiograph of the RED reaction products using (AAG)]0. Lanes 1-4: FAP generational 
pairs; lanes 5 and 6: control individuals. The samples loaded on lanes 7 to 12 are the same but 
resulting from a different cycling reaction. 10 ug of genomic DNA template were used in each 
reaction. Sizes of (AAG)„ multimers are indicated in bp. Note the reproducibility of the RED 
assay. 
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Figure 11. Autoradiograph of the RED reaction products using (AAG)i0. Lanes 1-5: control individuals; 
lanes 6-11: FAP generational pairs. 10 ug of genomic DNA were used in each reaction. Sizes of 
(AAG)n multimers are indicated in bp. 
62 
Results and Discussion 
II IV Ni N3 N7 O O D 
1 2 3 4 5 6 7 8 9 1011 1213 
* # 
Ni, □ 
14 
■ 
bp (AAG)„ 
540 I 
450 420 390 
360 
330 
— 300 
- - 270 
4 — 240 
d - 210 
d -■ 180 
# 
180 
170 
160 
150 
140 
130 
120 
110 
100 
90 
80 
70 
60 
* é - 150 50 
-* 120 40 
- 90 30 
« < * T — 60 20 
Figure 12. Autoradiograph of the RED reaction products using (AAG)i0. Lanes 1-10: FAP generational 
pairs; lanes 11 and 14: control individuals. 10 ug of genomic DNA template were used in each 
reaction. Sizes of (AAG)n multimers are indicated in bp. 
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Figure 13. Autoradiograph of the RED reaction products using (TTA)U. Lanes 1-4 and 12-14: control 
individuals; lanes 5-8: FAP generational pairs. 10 ug of genomic DNA template were used in 
each reaction. A single ligation product is seen in all samples. Sizes of (TTA)n multimers are 
indicated in bp. 
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3.4. AGT/ACT TRINUCLEOTIDE 
Genomic DNA of all FAP kindred pairs and 12 negative controls were used to 
determine AGT/ACT repeat lengths. Autoradiographs of AGT triplet RED reaction products are 
shown in Figures 14 and 15. The (AGT)i4 oligonucleotide was ligated only once in every 
sample, giving rise to a single band of 84 bp (28 repeats). The resulting products are clearly 
visible except in 2 control samples (Figure 14, lane 15; and Figure 15, lane 12) presenting feint 
bands. The descendant of pair VII (lane 8 of Figure 14) exhibits a different pattern of migration, 
observed in almost every reaction, characterized by a slower mobility throughout the gel which 
would accelerate further down to end ahead of all other sample bands. This phenomenon is 
probably due to the high viscosity of that particular DNA sample. The irregular bands observed 
in the film of Figure 15 reflect irregularities of the polyacrylamide gel when the nylon membrane 
was laid for DNA transfer, rather than different mobility patterns of the reaction products. 
AGT/ACT trinucleotide repeats have not been associated with any triplet repeat 
expansion disorder, and seem not to be polymorphic in size as observed in 57 unrelated 
Caucasian individuals, with a constant size of about 72 bp (one single ligation), using the RED 
method (Hofferbert et al., 1997). Our results support this view, although the size of the repeated 
motif has been determined to be slightly different due to the oligonucleotide number of repeated 
triplets. 
3.5. CGT/ACG TRINUCLEOTIDE 
The CGT/ACG repeat, tested with a (CGT)H oligonucleotide, was difficult to detect by 
the RED method. Figures 16 and 17 illustrate the RED reaction results in seven FAP 
generational pairs and 8 unrelated negative controls. The single oligonucleotide species appears 
at the bottom of the gel as large blots overlapping with several bands corresponding to ligation 
products of oligonucleotide fragments. The existence of such small products is indicative of 
oligonucleotide impurity which may have been responsible for the formation of very few ligated 
molecules during the cycling reaction. All samples show a faint band resulting from a single 
ligation and corresponding to 28 repeated triplets (84 bp). Hofferbert et ai. (1997) have shown 
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Figure 14. Autoradiograph of the RED reaction products using (AGT)i4. Lanes 1-10: FAP generational 
pairs; lanes 11 and 16: control individuals. 10 ug of genomic DNA template were used in each 
reaction. A single ligation product is seen in all samples. Sizes of (AGT)„ multimers are 
indicated in bp. 
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Figure 15. Autoradiograph of the RED reaction products using (AGT)i4. Lanes 1-4 and 12, 13: control 
individuals; lanes 5-11: FAP generational pairs. 10 ug of genomic DNA template were used in 
each reaction. A single ligation product is seen in all samples. Sizes of (AGT)n multimers are 
indicated in bp. 
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Figure 16. Autoradiograph of the RED reaction products using (CGT)i4. Lanes 2-9: FAP generational 
pairs; lanes 1 and 9-12: control individuals. 10 ug of genomic DNA template were used in each 
reaction. A feint band corresponding to a single ligation product is visible in all samples and is 
indicated by the arrow. The other bands result from the ligation of oligonucleotide fragments. 
Sizes of (CGT)n multimers are indicated in bp. 
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Figure 17. Autoradiograph of the RED reaction products using (CGT)i4. Lanes 1-6: FAP generational 
pairs; lanes 7-10: control individuals. 10 ug of genomic DNA template were used in each 
reaction. A feint band corresponding to a single ligation product is visible in all samples and is 
indicated by the arrow. The other bands result from the ligation of oligonucleotide fragments. 
Sizes of (CGT)„ multimers are indicated in bp. 
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a maximal size for CGT trinucleotide repeat of approximately 60 bp in 54 unrelated individuals, 
again the result of a single ligation of the oligonucleotide substrate [(CGTho]. Our results cannot 
exclude the existence of longer segments of repeated CGT triplets in the analyzed DNA 
samples, but the existing literature reports repeat lengths of less than 90 bp - 30 copies - of the 
repeated motif (Lindblad et al, 1994; Hofferbert et al, 1997) . Moreover, only one band 
resulting from a dimer formation has been consistently observed in all our experiments with this 
particular oligonucleotide. 
3.6. CGG/CCG TRINUCLEOTIDE 
Expansion of CGG triplets is associated with the fragile X syndrome leading to the loss 
of function of FMR1 protein (Pieretti et al, 1991). Disease-causing trinucleotide repeat lengths 
range from 200 triplets up to thousands of copies of the repeated motif. Premutation alleles, i.e., 
unstable triplet repeat segment-containing alleles exhibit a range of ~ 50 to 200 trinucleotide 
copies. 
The DNA from eight generational pairs and 8 normal individuals has been analysed for 
the presence of CGG repeat expansions. The results presented in Figures 18, 19 and 20 show 
the presence of a single band corresponding to a segment of 22 repeats (66 bp) in almost every 
sample. The RED reaction has not produced detectable amounts of substrate oligonucleotide 
dimers in 4 control individuals (Fig. 18, lane 12; Fig. 19, lanes 11, 12 and 13), in the second 
generation element of pair V and the progenitor of pair VIE (Fig. 20, lanes 3 and 8). Some of 
these samples exhibit a "smirr" throughout the gel, suggesting migration irregularities in addition 
to the weak repeat detection reaction. 
The absence of larger multimers of the (CGG)n oligonucleotide substrate is shown in 
every film, excluding the presence of another of the "potential candidates" in the tested FAP 
kindreds. Previous reports on CGG trinucleotide repeat lengths have revealed distinct fragments 
of 60 bp in 36 unrelated Caucasians and putative larger fragments of 90 to 120 bp in some of 
them (Hofferbert et al, 1997). This particular trinucleotide is difficult to detect by the RED 
method presumably due to secondary structure formation (Pearson and Sindren, 1996) or other 
processes that inhibit hybridization of the oligonucleotides. In order to resolve the former 
problem, we have added betaine to all the reaction mixtures to prevent impairment of 
oligonucleotide annealing resulting from hairpin or other complex DNA conformations. 
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Figure 18. Autoradiograph of the RED reaction products using (CGG)U. Lanes 1-8: FAP generational 
pairs; lanes 9-12: control individuals. 10 ng of genomic DNA template were used in each 
reaction. A single ligation product is seen in almost every sample. Sizes of (CGG)„ multimers 
are indicated in bp. 
71 
Results and Discussion 
n m .—. N3N4N13 
#-i #-, ÉêOOO 
1 2 3 4 5 6 7 8 9 
Ni4N16 NIT 
O O D 
10 11 12 
bp (CGG)„ 
- 66 22 
Figure 19. Autoradiograph of the RED reaction products using (CGG)n. Lanes 1-6: FAP generational 
pairs; lanes 7-12: control individuals. 10 ug of genomic DNA template were used in each 
reaction. A single ligation product is seen in lanes 1-6 and 7; the remaining reactions did not 
work. Sizes of (CGG)„ multimers are indicated in bp. 
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Figure 20. Autoradiograph of the RED reaction products using (CGG)n. Lanes 1 and 11-13: control 
individuals; lanes 2-10: FAP generational pairs. 10 ug of genomic DNA template were used in 
each reaction. A single ligation product is seen in all samples except in lane 3. Sizes of (CGG)„ 
multimers are indicated in bp. 
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3.7. TGG/CCA TRINUCLEOTIDE 
The maximal repeat size obtained for TGG/CAA trinucleotide ranged between 72 bp 
(24 repeats) and 144 bp (48 repeats) corresponding to the formation of dimers to tetramers of 
the oligonucleotide substrate, respectively (Figures 21 and 22). The exact repeat sizes were 
difficult to assess in all samples since the RED reactions have generated weak signals. 
All generational pairs and eleven control individuals were used for triplet repeat size 
detection. Distinct fragments of 72 bp (24 repeated units) could be detected in all samples. In 
pairs I to HI, fragments of 108 bp and 144 bp could also be seen (Figure 21, lanes 2-7). Pair IV 
also presented the 108 bp band and a putative larger fragment of 144 bp (48 repeated triplets) 
(lanes 7 and 8 of Figure 22). All the other pairs exhibit a weak signal and the presence of larger 
multimers of (TGG)i2 cannot be excluded (data not shown). The control DNA samples were 
found to have repeat lengths of 72 and 108 bp resulting from the ligation of 2 or 3 oligos, 
respectively. The feint bands observed for the control samples and for those of pairs V to VIE 
are suggestive of a low yield reaction, perhaps producing an incorrect estimate of the genomic 
trinucleotide repeat length. In any case, our results do not show any difference in repeat size 
within the FAP generational pairs, thus excluding the presence of TGG trinucleotide unstable 
expansions from one generation to the other. Moreover, the estimated sizes ranges are in 
accordance with previous studies where the repeat lengths vary between 120 and 210 bp 
(Lindblad et al., 1995; Hofferbert et al., 1997). 
3.8. ATG/CAT TRINUCLEOTIDE 
The results of ATG/CAT trinucleotide repeat size detection are shown in Figures 23 and 
24. Seven FAP kindred pairs and 10 control individuals present maximal repeat sizes ranging 
between 24 repeated triplets (72 bp) and 48 repeats (144 bp). All pairs exhibit 3 bands 
corresponding to the ligation of four (ATG)i2 oligonucleotides (144 bp), the third band being 
very feint in pair VI due to a weaker reaction (Figure 24, lanes 5, 6). Repeat detection was not 
successful above the 72 bp fragment for pair V and the progenitor of pair VIE, and the 108 bp 
fragment for the descendent of pair VII (lanes 4, 5, 10 and 8 of Figure 24, respectively). It is 
clear by comparison with the signals obtained for all the other samples that formation of 
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Figure 21. Autoradiograph of the RED reaction products using (TGG)12. Lanes 1-7: FAP generational 
pairs; lanes 8-13: control individuals. 10 ug of genomic DNA template were used in each 
reaction. Note the reduced (TGG)I2 multimer formation in lanes 9 and 11-13. Sizes of (TGG)„ 
multimers are indicated in bp. 
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Figure 22. Autoradiograph of the RED reaction products using (TGG)i2. Lanes 1-8: FAP generational 
pairs; lanes 9-12: control individuals. 10 ug of genomic DNA template were used in each 
reaction. Sizes of (TGG)„ multimers are indicated in bp. 
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oligonucleotide multimers was much lower in the referred individuals, suggesting that the same 
sizes would be detected if the cycling reaction efficiency had been the same. Identical results 
were obtained with the control DNA samples where the reaction-generated (ATG)i2 multimers 
are clearly insufficient for the correct genomic repeat length detection. Hofferbert et al. (1997) 
have reported a distribution of maximal repeat sizes in 31 unrelated individuals ranging between 
60 bp and 240 bp, with a high frequency of 120 bp repeat-containing positives. The repeat 
lengths obtained in our experiments fall in the medium range of the reported size spectrum. 
The triplet repeat lengths are conserved within each tested generational pair arguing 
against the involvement of an ATG trinucleotide expansion as the responsible mechanism for 
genetic anticipation in these FAP patients. 
3.9. GTT/AAC TRINUCLEOTIDE 
The GTT/AAC triplet repeat was difficult to detect by the RED method. The repeat 
detection reactions have not produced detectable amounts of (GTT)i5 oligonucleotide multimers 
in most of the experiments, resulting in the absence of ligation-corresponding bands. Figure 25 
represents the only reaction in which a single band was obtained. It is not possible, however,, to 
determine if it corresponds to the oligonucleotide itself or to the product of a single ligation 
referring to a 90 bp fragment (30 repeats). The shape of the bands more resembles the product 
of a dimer formation rather than a single oligonucleotide species, which would be in accordance 
with the reported sizes for this triplet in 54 unrelated Caucasians where the maximal repeat 
length was 90 bp (Hofferbert et a/., 1997). If that is the case, our results shown the absence of 
any differences in size distribution among the members of four FAP generational pairs (V to 
VIE) and 5 control individuals, excluding GTT/AAC repeat expansions as the molecular basis 
for the phenomenon of anticipation. 
3.10. CCT/AGG TRINUCLEOTIDE 
The detection of CCT/AGG genomic repeat lengths by the RED method was a 
technical Mure. Multimers of (CCT)i5 oligonucleotide substrate were never formed in any 
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Figure 23. Autoradiograph of the RED reaction products using (ATG)12. Lanes 1-10: FAP generational 
pairs; lanes 11-13: control individuals. 10 ng of genomic DNA template were used in each 
reaction. Note the reduced (ATG)12 multimer formation in lanes 9 and 11-13. Sizes of (ATG),, 
multimers are indicated in bp. 
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Figure 24. Autoradiograph of the RED reaction products using (ATG)12. Lanes 1-7: FAP generational 
pairs; lanes 8-13: control individuals. 10 \ig of genomic DNA template were used in each 
reaction. Note the reduced (ATG)i2 multimer formation in lanes 9 and 11-13. Sizes of (ATG)„ 
multimers are indicated in bp. 
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Figure 25. Autoradiograph of the RED reaction products using (GTT)i5. Lanes 1-8: FAP generational 
pairs; lanes 9-13: control individuals. 10 ng of genomic DNA template were used m each 
reaction. The band seen in all samples resembles the product of one ligation, but it can also 
correspond to the single oligonucleotide species. The size of the putative (GTT)15 dimer is 
indicated in bp. 
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experiment and only one band corresponding to the single oligonucleotide species was clearly 
visible in all RED reactions (data not shown), ruling out radiolabeled probe hybridization 
problems. The reasons why repeat detection has not been possible are not known, however it is 
most likely that the problem lies on the cycling reaction itself where the oligonucleotide 
annealing with the genomic DNA might have been impaired. Oligonucleotide impurity, for 
example, could be the origin for the reaction failure. 
The absence of any results prevent us to draw any conclusion about this trinucleotide 
involvement in genetic anticipation in the tested kindreds, however the expected maximal repeat 
sizes for this triplet, as determined by RED in 35 unrelated individuals, is 90 bp corresponding 
to a trimer of the used oligonucleotide substrate (Hofferbert, 1997). 
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While the initially described disorders caused by trinucleotide repeat expansions (TREs) 
were limited to CGG/CCG and CTG/CAG repeats, the recent discovery of an intronic GAA 
repeat expansion as the cause of Friedreich's ataxia has shown that other TREs exist and have 
disease-causing potential. The genetic instability of the expanded triplets results in increased 
precocity, severity or penetrance in successive generations, a phenomenon known as genetic 
anticipation. Indeed, eleven of the twelve triplet repeat-associated disorders exhibit a marked 
anticipation of the age-at-onset, and/or increased severity of symptoms over generations. The 
number of trinucleotide repeats appears to be correlated with the age of onset as increased 
repeat copy number results in phenotypic anticipation. Anticipation cannot be seen in autosomal 
recessive disorders, because they usually affect only a single generation, which makes FA the 
sole disorder with little evidence for this phenomenon. Since dynamic mutations are the only 
known molecular mechanism explaining genetic anticipation, other neurological or 
neuropsychiatrie disorders with dominant inheritance and obvious anticipation are being 
intensively investigated for associated dynamic mutations. 
FAP is a potential candidate for a dynamic mutation-associated disorder, as a 
neurological disease with autosomal dominant inheritance exhibiting genetic anticipation. 
However, it is more than likely that such a mutation would occur in a modifier gene (or genes), 
rather than the TTR gene. The TTR gene does not contain repeated motifs apart from two short 
(CA)n stretches in the regulatory sequences of the 5' untranslated region (Sakaki, 1989). 
Nonetheless, the existence of modifier genes underlying phenotypic heterogeneity in FAP, 
particularly manifested as anticipation of the age-at-onset, is a possibility. To address this 
question we have used the Repeat Expansion Detection (RED) technique that allows a genome-
wide analysis for TREs (Schalling et al, 1993; Sirugo et al, 1995). The RED assay has been 
applied to search for triplet expansions in common neuropsychiatrie disorders with anticipation 
(Lindblad et al, 1995; Morris et al, 1995), and to determine triplet repeat size polymorphisms 
in individuals of several populations (Watkins et al, 1995; Hofferbert et al, 1997; Nakamoto et 
al, 1997). For instance, Carrero-Valenzuela et al (1995) have excluded the association of 
familial Parkinson's disease with CAG/CTG expansions, using the RED technique. 
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We have scanned eight generational pairs of Portuguese FAP kindreds exhibiting 
marked anticipation of the age-at-onset (the differences within the pairs being greater than 12 
years), and 19 unrelated healthy Portuguese individuals, for the existence of intergenerational 
instability of the ten possible triplet repeats. 
Our experiments have defined the triplet repeat sizes for 8 out of the 10 trinucleotides. 
The determined repeat lengths fall in the range of the expected size spectrum when compared 
with previously reported data (Lindblad et al, 1994 and 1995; Schalling et al, 1993; Hofferbert 
et al, 1997; Nakamoto et al, 1997). The RED reactions testing CTG, CGG, and AAG triplets -
the known disease-causing motifs - have produced large amounts of oligonucleotide multimers 
allowing good detection of the repeated triplet sizes in all screened individuals. Our analysis of 
genomic DNA from 9 FAP generational pairs and 8 unrelated control individuals for CTG/CAG 
triplet repeats (expanded in 8 neurodegenerative disorders), revealed a high frequency of 120 bp 
repeat-containing positives, the repeat size being exactly the same within the FAP kindred pairs. 
Only one pair was found to exceed this copy number, albeit without exceeding the expected 
repeat length for normal alleles or exhibiting intergenerational expansion of the triplet repeat. 
The use of a positive control DNA sample containing a very long segment of CTG repeats has 
proved the detectability of expansion of a single copy allele under our experimental conditions. 
For the CGG repeat, the cause of fragile X syndrome, a small repeat size corresponding 
to 22 trinucleotide copies was detected in nearly all screened individuals. Difficulties in 
detecting repeated CGG triplets were reported by Hofferbert et al (1997) being attributed to 
secondary structure formation on template DNA with (C+G)-rich repeats (Person and Sinden, 
1996). We circumvented that problem by using betaine, a reagent that weakens C-G annealing, 
preventing the formation of secondary structures that could inhibit oligonucleotide hybridization 
to the single stranded genomic template. The CGG repeat length determined in our experiments 
is similar to previously reported data (Hofferbert et al, 1997) and clearly shows the absence of 
any unstable expansion in the screened FAP individuals. 
For the AAG repeat - expanded in FA - large maximal repeat sizes have been detected, 
particularly in the screened FAP individuals. The (AAG)io oligonucleotide revealed repeat 
lengths up to 600 bp (200 repeats). The presence of large multimers close to the upper 
resolution of the gel was carefully assessed in order to determine the exact repeat sizes of the 
samples. Moreover some samples were scanned in duplicate to ascertain the determined sizes. 
Although the band readings are relatively difficult in that particular portion of the gel, no 
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differences in size were observed among the members of each pair, with the exception of pairs I 
and H, presenting a difference of a single oligonucleotide ligation favoring a contraction and an 
expansion, respectively. These results allow us to exclude the existence of unstable expansions 
in second generation individuals of the FAP pairs. 
TTA, AGT, and CGT trinucleotides have been shown to present monomorphic repeat 
lengths, clearly ruling out anticipation-related intergenerational instability in the scanned FAP 
kindred pairs. RED reaction experiments with the CGT oligonucleotide have produced a very 
weak signal. The low yielding reactions are most certainly caused by oligonucleotide 
contaminants, as previously mentioned, expressed by the detection of very small fragments of 
the oligo substrate either alone or ligated, forming longer single stranded molecule species and 
appearing as a ladder below the CGT dimer position. The faint band immediately over the 84 bp 
fragment corresponding to the single ligation also results from the same contamination. As it will 
be discussed later, RED technique is very sensitive to the purity of the oligonucleotides and 
genomic DNA templates. 
When compared to previously reported data, the frequency of trinucleotide repeats at or 
above discrete lengths seemed to by similar for TGG and ATG. The determined triplet repeat 
lengths fall in the polymorphic size range spectrum observed in healthy unrelated Caucasians 
(Hofferbert et al, 1997), and are identical within each scanned FAP generational pair arguing 
against the involvement of unstable expansions in these kindreds. 
Our analysis of genomic DNA from the FAP kindred pairs and control individuals was 
unsuccessful for GTT and CCT triplets and did not allow the determination of maximal triplet 
repeat sizes. A doubt remains regarding GTT trinucleotide RED results since the single band 
obtained in one experiment might correspond to the ligation of the (GTT) 15 substrate, rather than 
to the oligonucleotide monomer. 
The power and limitations of the RED assay have been evaluated by Hofferbert et al. 
(1997). A dilution series of cloned trinucleotide repeats with known sizes has defined 10 \ig as 
the required amount of DNA to detected the expansion of a TNR in one allele of a single copy 
gene. Twenty diagnosed HD probands with previously determined sizes of the expanded HD 
gene were tested with the RED method. The CTG repeat sizes, as determined by RED, were 
never smaller than the actual repeat size, matching exactly the repeat lengths in 8 samples and 
exceeding the previously determined sizes in 12 cases. The results obtained with the control 
population suggested that those differences were due to CTG/CAG expansions in the genome 
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unrelated to the HD locus. CTG/CAG repeat lengths in normal alleles have been shown to 
exceed the copy number expected for non-diseased individuals, i.e., falling in the premutation or 
mutation size range spectrum of the TRE-associated diseases, suggesting the existence of other 
expansions unrelated to the loci of those disorders (Nakamoto et ai, 1997). 
In addition to the sensitivity of the RED technique, evaluated by Hofferbert and co-
workers, we have assessed the reproducibility of the RED method, by scanning some samples in 
duplicate or triplicate for CTG, CGG and AAG triplets. The maximal repeat sizes obtained were 
identical in all cases. The autoradiograph shown in Figure 10 illustrates well the reproducibility 
of the RED assay, exhibiting identical products from different cycling reactions using the same 
samples. Our experiments have also shown that the RED reaction is very sensitive to small 
variations in the cycling conditions and to the purity of the oligonucleotides and genomic DNA 
template. The weak signals presented by some samples are consistently observed in most of the 
RED experiments in which they have been used, suggesting a certain degree if impurity that 
results in a low formation of oligonucleotide multimers. The hybridization of the oligonucleotide 
substrate to the genomic template might be impaired resulting in decreased formation of ligated 
products. The existence of contaminants in the oligonucleotide solution is also suggested by the 
ladder of bands appearing below the oligo multimer products, as observed, for instance, in the 
CGT triplet expansion reaction. The presence of contaminants is likely to slow down the 
annealing and ligation processes, resulting in low multimer production. The radiolabeled probe 
hybridization to the RED reaction products were not responsible for the faint bands obtained in 
some autoradiographs since there were always samples with strong signals, arising from a 
normal labeling procedure. In general, the RED assay is a reliable method for the detection of 
triplet repeat expansions in the human genome and has been shown to be capable of detecting 
even small expansions against a background of polymorphic larger repeated sizes as long as the 
population is homogeneous (Hofferbert et al, 1997). 
Our results show the absence of any size differences between the elements of the FAP 
generational pairs, excluding the involvement of intergenerational unstable triplet expansions as 
the underlying mechanism for genetic anticipation in these kindreds, for the eight successfully 
tested trinucleotides. No conclusions can be drawn regarding GTT and CCT triplets since the 
respective RED experiments have been unsuccessful. It should noticed, however, that expansion 
of any of these two trinucleotides has not been associated with any prior instance of anticipation. 
A limitation of our experiments was the absence of positive controls which would prove 
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the detectability of a single copy allele expansion under our experimental conditions. We have 
used a positive control only for CTG/CAG trinucleotide repeat detection, showing that the 
reaction conditions were perfectly adequate for genomic CTG repeat detection. Although all 
other RED assays were performed without positive controls, the determined repeat lengths were 
in accordance with previously reports, suggesting that the experimental conditions were suitable 
for the exact repeat size detection. 
The number of scanned FAP kindred generational pairs constitute a relatively small 
sample of the Portuguese kindreds exhibiting anticipation. In a study with 227 generational pairs 
of Portuguese FAP kindreds, Sousa (1995) has reported anticipation of the age-at-onset in 
approximately 60% of the pairs. Considering that the Portuguese population is homogeneous 
and relatively constrained in reproductive terms, we would expect to find an unstable 
trinucleotide expansion in at least one pair if such mutation would indeed be responsible for 
phenotypic anticipation in FAP. A statistical analysis of our results suggests that no more than 
11% [(95% CI (0-37%)] of the Portuguese FAP kindreds exhibiting anticipation is likely to have 
TREs as the underlying mechanism. The distribution of maximal triplet repeat sizes both for the 
FAP individuals and the unrelated controls, as determined by RED, is rather uniform, implying 
that the Portuguese population is genetically homogeneous with respect to genomic triplet repeat 
sequence lengths, although our sample size is too small to make a definitive statement. 
Our results are suggestive - within the sensitivity and limitations of the RED method -
that trinucleotide repeat expansions are unlikely to be responsible for genetic anticipation in FAP 
kindreds in the Portuguese population. To further substantiate our conclusions, additional pairs 
should be scanned for triplet repeat expansions. 
This study has not excluded dynamic mutation as a potential molecular mechanism 
responsible for genetic anticipation in FAP. Several other simple tandem repeats are known to 
be unstable in the human genome and the cause of expansion-related disorders (Lalioti et al. 
1997; Lafrenière et ai, 1997). The role of environmental factors in phenotypic anticipation in 
FAP cannot be excluded but is very unlikely. The involvement of multiple genes in TTR 
amyloidogenesis is strongly suggested, justifying a genome-wide scanning for modifier genes by 
genetic linkage analysis and positional cloning. The detection of TREs systematically in a 
significant proportion of FAP kindreds, would suggest that the gene bearing the expansion 
responsible for anticipation might be one such modifier gene. Thus, the search for TREs in FAP 
represents the first approach to assess the molecular basis for genetic anticipation and could 
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provide insight into the mechanisms of pathology at the cellular level, with immediate 
applications on genetic counseling. Furthermore, the identification of protein products of the 
TREs in amyloidogenesis, might help to elucidate the mechanism of amyloid deposition with 
important consequences at the therapeutic level. 
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Appendices 
Appendices 
1. Abbreviations for Amino acids 
AMINO ACIDS THREE-LETTER 
ABBREVIATION 
Alanine Ala 
Arginine Arg 
Asparagine Asn 
Asparticacid Asp 
Cysteine Cys 
Glutamine Gin 
Glutamic acid Glu 
Glycine Gly 
Histidine His 
Isoleucine fle 
Leucine Leu 
Lysine Lys 
Methionine Met 
Phenylalanine Phe 
Proline Pro 
Serine Ser 
Threonine Thr 
Tryptophan Trp 
Tyrosine Tyr 
Valine Val 
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2. The Genetic Code 
Second position 
U C A G 
u UUU Phe 
UUC Phe 
UUA Leu 
UUG Leu 
UCU Ser 
UCC Ser 
UCA Ser 
UCG Ser 
UAU Tyr 
UAC Tyr 
UCA Stop 
UCG Stop 
UGU Cys 
UGC Cys 
UGA Stop 
UGGTry 
U 
C 
A 
G 
c CUU Leu 
CUC Leu 
CUA Leu 
CUG Leu 
CCU Pro 
CCC Pro 
CCA Pro 
CCG Pro 
CAU His 
CAC His 
CAAGin 
CAG Gin 
CGU Arg 
CGC Arg 
CGAArg 
CGG Arg 
U 
C 
A 
G 
A AUU lie 
AUC He 
AU A He 
AUG He 
ACU Thr 
ACC Thr 
ACAThr 
ACG Thr 
AAUAsn 
AACAsn 
AAA Lys 
AAGLys 
AGU Ser 
AGC Ser 
AGA Arg 
AGG Arg 
U 
C 
A 
G 
G GUU Val 
GUC Val 
GUAVal 
GUG Val 
GCU Ala 
GCC Ala 
GCAAIa 
GCG Ala 
GAU Asp 
GAC Asp 
GAAGIu 
GAG Glu 
GGU Gly 
GGC Gly 
GGA Gly 
GGG Gly 
U 
C 
A 
G 
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